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Riassunto
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Nonostante le malattie cardiovascolari siano percepite come malattie in 
prevalenza maschili, numerosi dati clinici ed epidemiologici dimostrano che 
riguardano anche le donne. Quello che differenzia i due generi è che nelle donne 
si presentano con un ritardo di almeno 10 anni rispetto agli uomini in quanto si 
ritiene che le donne siano protette, perlomeno fino alla menopausa, dagli 
estrogeni. La solidità dei dati clinici ed epidemiologici non si associa però a 
un’altrettanto approfondita conoscenza dei meccanismi biologici e molecolari che 
stanno alla base di queste differenze. Va ricordato che nella complessa serie di 
eventi che sfocia nell’aterosclerosi e nella malattia cardiovascolare, il primo 
passaggio è rappresentato da una perdita di funzionalità dell’endotelio, la 
cosiddetta disfunzione endoteliale. Poiché molto poco si conosce sulle proprietà 
innate di cellule endoteliali (EC) maschili e femminili ci è parso particolarmente 
interessante indagare le caratteristiche di EC umane in coltura primaria derivate 
da cordoni ombelicali di donatori di sesso maschile o femminile (HUVECs, 
abbreviate rispettivamente in M-EC e F-EC).  
 
 Nostro primo obiettivo è stato lo studio dell’influenza degli estrogeni sulle 
proprietà delle M-EC e F-EC. A tale scopo, abbiamo utilizzato un terreno di 
coltura privo di ormoni contenente siero fetale bovino sottoposto a procedura di 
stripping (CS-FBS). In queste condizioni, sia le M-EC che le F-EC hanno mostrato 
una riduzione della crescita e delle proprietà angiogeniche in vitro che la 
riaggiunta degli ormoni sessuali nel mezzo di coltura non è stata in grado di 
prevenire. Poiché l’effetto inibitorio di CS-FBS è revertito dall’aggiunta di FBS 
normale al terreno di coltura, ci siamo focalizzati sugli acidi grassi (FA) per due 
ragioni: i) non sono presenti nel CS-FBS; ii) la loro ossidazione è necessaria per 
la crescita delle EC e per l’angiogenesi. Infatti, l’aggiunta di acetato, un donatore 
di acetil-CoA, o di acido palmitico è stata in grado di revertire significativamente 
in entrambi i sessi l’inibizione della crescita e dello sprouting indotta da CS-FBS. 
Questi risultati confermano il ruolo centrale degli FA nella fisiologia delle EC sia 
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maschili che femminili, e suggeriscono cautela nell’utilizzo di terreni contenenti 
CS-FBS per lo studio delle EC. 
 
 In una successiva serie di esperimenti, abbiamo rivolto la nostra 
attenzione all’espressione e all’attività di eNOS in M-EC e F-EC, considerato il 
ruolo cruciale dell’enzima e del suo prodotto NO nella fisiologia dell’endotelio. 
Abbiamo innanzitutto osservato che le F-EC esprimono costitutivamente una 
maggiore quantità di eNOS, a livello sia di mRNA che di proteina, rispetto alle M-
EC. Alla ricerca del significato biologico di questa differenza, abbiamo osservato 
che le F-EC hanno maggiori capacità migratorie rispetto alle M-EC, e soprattutto 
che la motilità di F-EC e M-EC differisce in maniera significativa nella dipendenza 
da eNOS. La migrazione delle F-EC è infatti ridotta dal silenziamento e 
dall’inibizione farmacologica di eNOS, che lasciano invece pressoché invariata la 
capacità migratoria delle M-EC. Abbiamo poi paragonato il contributo di 
migrazione e proliferazione al processo di sprouting delle M-EC e F-EC in un 
saggio 3-D di angiogenesi in vitro in cui è stata confermata la stretta dipendenza 
delle F-EC dall’attività di eNOS e dalla migrazione. Al contrario, le M-EC 
mostrano una stringente dipendenza dalla proliferazione che non coinvolge 
l’attività di eNOS.  
 
 In conclusione, a differenza delle M-EC, le F-EC sembrano essere 
strettamente dipendenti dall’attività di eNOS per la migrazione e lo sprouting. La 
maggiore espressione costitutiva di eNOS nelle F-EC potrebbe contribuire alla 
protezione contro le malattie cardiovascolari che caratterizza la popolazione 
femminile prima della menopausa, e suggerire lo sviluppo di nuove strategie 
sex-oriented per la prevenzione e la terapia delle malattie cardiovascolari.  
  
 
Abstract
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Atherosclerosis and cardiovascular disease (CVD) are classical examples of 
diseases where sex/gender differences have been described. A significant body 
of evidence suggests that CVD is less prevalent in women than men until midlife, 
and the female advantage has been attributed to estrogens, which are lost with 
menopause. The earliest event in the onset of atherosclerosis and CVD is 
endothelial dysfunction (ED). For this reason, many in vitro studies have been 
performed in endothelial cells (ECs). However, the sex of ECs has not been 
consistently reported. Therefore, we thought of interest to compare  the 
behavioral and molecular features of human primary male and female ECs 
obtained from umbilical cords (HUVECs, abbreviated as M-ECs and F-ECs, 
respectively) . 
 
 To study the involvement of estrogens in the sex-related properties of 
ECs, we started by culturing HUVECs in a nominally hormone-free medium 
supplemented with charcoal-stripped serum (CS-FBS) commonly used for in vitro 
studies on hormone activities. Surprisingly, we found that both M-ECs and F-ECs 
underwent a significant decrease in cell number which was not reverted  when 
sex hormones were added back to the culture medium. In addition, the presence 
of CS-FBS abrogated the ability of M-ECs and F-ECs to sprout in an in vitro 3-D 
angiogenesis assay. Since the inhibitory effect of CS-FBS was fully reverted by 
the re-addition of normal FBS, we focused our attention on fatty acids (FAs), 
that are lost in CS-FBS and that are crucially involved through their oxidation in 
the control of EC behavior. Reconstitution experiments performed by re-adding 
the acetyl-CoA precursor acetate or palmitic acid partially prevented the CS-FBS-
induced inhibition of EC growth and sprouting. Therefore, a lack of FAs seems to 
be partly responsible for the impairment in the in vitro proliferative and 
angiogenic properties of M-ECs and F-ECs cultured in CS-FBS containing media.  
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 A reduced activity of eNOS plays a key role in CVD onset and 
development through the reduced formation of nitric oxide (NO) in ED. 
Therefore, we focused on the expression and the role of the enzyme in M-ECs 
and F-ECs. Interestingly, we found that F-ECs constitutively expressed an higher 
amount of eNOS both at mRNA and protein levels. Moreover, F-ECs possessed 
greater migratory capabilities in comparison to M-ECs. Importantly, the 
increased female migratory properties were counteracted by the treatment with 
the eNOS inhibitor L-NAME or by the silencing of the enzyme. At variance, M-EC 
motility was independent of eNOS activity.  
Since angiogenesis is the result of a coordinated process where the migration of 
specialized cells – the tip cells – and the proliferation of the so-called stalk cells 
both contribute to the growth of new vessels, we evaluated in an in vitro 3-D 
spheroid assay the relative contribute of motility and proliferation to the M-EC 
and F-EC sprouting process.  Notably, F-ECs confirmed their strictly dependence 
on migration and eNOS activity, whereas M-ECs showed a more important 
reliance on proliferation which was eNOS-independent. The different migratory 
behavior between M-ECs and F-ECs was confirmed in mixed spheroids from GFP-
carrying M-ECs and Cherry Red-expressing F-ECs where the analysis of sprouts 
showed that F-ECs were located as tip cells in most of the sprouts.  
 
In conclusions, our results show that F-ECs have a higher migratory phenotype 
in comparison to M-ECs and are strictly dependent on eNOS activity for their 
migration and sprouting. The constitutive higher expression of eNOS in F-ECs, 
and the crucial requirement of its activity for motility and in vitro angiogenesis, 
might contribute to the protection against CVD characteristic of the younger 
female population, and might propose the development of novel sex-oriented 
strategies for the prevention and therapy of CVD.     
  
Introduction
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1. Cardiovascular disease  
 
Cardiovascular disease (CVD) is a group of disorders of the heart and blood 
vessels that includes coronary artery diseases, cardiomyopathy, stroke, 
hypertensive heart disease, congenital heart disease, rheumatic heart 
disease, heart arrhythmia, valvular heart disease, aortic aneurysms, 
peripheral artery disease and venous thrombosis.  
 
CVD is globally the most common cause of death. It accounts for 31.5% of 
all deaths, more than twice than the deceases caused by cancer1. It has 
been estimated by the Global Burden of Disease (GBD) that CVD has been 
responsible for 17.3 million deceases worldwide in 2013. 
 
CVD and stroke globally produce huge health and economic burdens. For 
2011 to 2012, the estimated annual costs for CVD and stroke in the United 
States were $316.6 billion, including direct (hospital services, prescribed 
medications, home health care) and indirect costs (in terms of lost of future 
productivity for cardiovascular and stroke premature deaths). CVD costs 
more than any other diagnostic group. By comparison, in 2011, the 
estimated direct cost of all cancers was half of CVD direct cost2.  
 
1.1 Risk factors for CVD 
 
CVD can be prevented by addressing behavioral risk factors. Lifestyle-
related risk factors are the foremost causes of death and disability in the 
world. The leading risk factor for CVD in the United States is the suboptimal 
diet quality that correlates with overweight and obesity, thus predisposing 
individuals to most major risk factors, including physical inactivity, 
hypertension, hyperlipidemia, and diabetes mellitus. Although tobacco use 
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has substantially declined in the United States, it remains the second-
leading cause of total deaths and disability. Likewise, harmful alcohol 
consumption predisposes individuals to the development of CVD. 
 
Next to behavioral risk factors, there are other important health risk factors, 
that include genetics, high blood pressure, diabetes, lipid levels, high blood 
cholesterol, and metabolic syndrome. Furthermore, vascular ageing 
contributes to the age-dependent rise in hypertension and atherosclerotic 
disease, and confers itself a greater risk for CVD than all of the other 
conventional risk factors3.  
 
A common feature of all cardiovascular risk factors mentioned above is the 
loss of endothelial function that precedes the development of vascular 
disease. Specifically, endothelial dysfunction (ED) is a systemic pathological 
state of the endothelium that occurs when the endothelium fails to sustain 
its normal physiologic mechanisms4.  ED could be useful as a highly 
sensitive marker for the overall cardiac risk. Indeed, it has been reported5,6 
that patients with ED have greater chances of having a cardiac event 
compared to patients showing a normal endothelial function.  
 
1.2 Sex differences in CVD 
 
A significant body of epidemiological and clinical data emphasizes that sex 
differences play a major role in CVD7. It has been reported that the total 
number of deaths from CVD is higher in women (49% of all deaths) than 
men (40% of all deaths). However, more men (0.9 million) than women (0.5 
million) die from CVD before the age of 758. The observed sex differences 
are greater at younger ages, with CVD less prevalent in women than men 
until midlife (Figure I). 
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Figure I. Prevalence of CVD in men and women. From World Journal of 
Cardiology (2009) 1, 295-302  
 
These significant sex differences also exist in the occurrence of various 
manifestations of CVD. It has been reported that the risk of developing 
coronary heart disease is higher in men than in women, particularly at 
younger ages. But women are more likely to develop cerebro-vascular 
disease or heart failure as a first event, and have greater microvascular 
dysfunctions relative to men, although these manifestations appear at older 
ages9,10.  
 
An important body of evidence supports the idea that the female risk for 
CVD increases more quickly than it does for same-aged men after the 
menopause11. The female advantage in younger women has been attributed 
to vascular protection by estrogens, which is lost with menopause. In 
premenopausal women, the high levels of endogenous estrogens have been 
linked to a lower risk for a number of diseases, such as hypertension, 
vascular disease, stroke, diabetes mellitus and obesity, compared to age-
matched men12. During the menstrual cycle, blood pressure levels lower 
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when estrogen levels peak, reflecting their vasodilator activity. Similarly, the 
increase in endogenous estrogen production during pregnancy contributes to 
the maintenance of a normal blood pressure13. In addition, chronic estrogen 
treatment enhances the endothelium-dependent vasodilation of large 
peripheral arteries in post-menopausal women14. 
 
Sex differences in the manifestation of CVD have also been observed in 
different animal models where the protective role of estrogens has been 
confirmed7. For example, female rodent hearts are more resistant to 
ischemia/reperfusion-induced injury15 and myocardial infarction16,17, thus 
suggesting a cardio-protective role for estrogens in female animals. 
Moreover, the endothelium-dependent relaxations are more pronounced in  
the arteries of young female animals than in males. Ovariectomy causes 
blunting of such responses, whereas reintroduction of physiological levels of 
estrogens potentiates them18. Furthermore, the experimental administration 
of estrogens reduces the infarct size in rabbit, mice, and rat19,20,21. 
 
Increasing evidence suggest that differences between male and female are 
according to sex, regardless of their exposure to sex hormones22,23,24. But, 
despite the evidence of important sex/gender differences in both rodent and 
human endothelial function10,25,26, the sex of cells has not consistently taken 
in account in studies involving endothelial cells (ECs), even when the effects 
of sex hormones have been analyzed. As a consequence, our knowledge on 
the molecular mechanism(s) underlying sex-based differences in 
cardiovascular physiology and disease is currently incomplete7,27. However, 
some inborn sex differences appear when primary cultures of human male 
and female ECs have been independently studied28,29,30,31. 
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The presence of innate differences between male and female could have 
major implications for the susceptibility to many diseases, and for their 
diagnosis and treatment. Nevertheless, it is more likely that sex differences 
in cardiovascular physiology and pathology are the result of multiple factors, 
arising from genetic differences (e.g., X and Y chromosomes, epigenetic 
modulation), from the action of sex steroid hormones (e.g., estrogen and/or 
testosterone), or from a combination of all these factors. 
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2. The endothelium  
 
The vascular endothelium is constituted by a monolayer of thin and flat cells 
– the endothelial cells (ECs) – that forms the inner continuous lining of blood 
vessels32. It represents an important structural barrier between the 
circulation and the surrounding tissues, thus regulating the transfer of small 
and large molecules across them33,34.  
 
2.1 Physiology 
 
The primary function of endothelium -  and ECs - is the control of vascular 
homeostasis by modulating the blood vessel tone. To this purpose, ECs 
produce and release vasodilators such as nitric oxide (NO) and prostacyclin 
(PGI2), and vasoconstrictors, including platelet-activating factor (PAF) and 
endothelin (ET). Among vasodilator substances, NO is certainly the most 
important. Its production is modulated by a number of exogenous chemical 
and physical stimuli, and NO profoundly affects the function of the 
underlying vascular smooth muscle cells (VSMCs) to maintain an optimal 
blood vessel tone33. 
 
Another crucial physiological function of the endothelium is the maintenance 
of a non-thrombogenic blood-tissue interface to inhibit platelet adhesion and 
clotting, and to facilitate blood flow. The endothelium exerts its 
anticoagulant activity through the action of several factors, such as for 
example anti-thrombin III and heparin co-factor II. Other anticoagulant 
factors produced by the endothelium are the Tissue Factor Pathway Inhibitor 
(TFPI) - which inhibits the binding of the tissue factor-activated factor VII to 
the activated factor X35 - and thrombomodulin (TM) – that, in complex with 
the activated protein C, can associate to the co-factor protein S, with an 
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increase in its anticoagulant activity32. A homeostatic equilibrium between 
anti- and pro-thrombotic factors is always present. This dynamic equilibrium 
is however perturbed during injuries, or when the endothelium is exposed to 
physical forces (shear or tensile stress) or mediators such as thrombin, 
endotoxin, cytokines, hypoxia, or oxidized lipids36. In response to these 
conditions, ECs undergo programmatic biochemical changes that culminate 
in their transformation into a pro-thrombotic surface. Importantly, ECs can 
easily return to the unperturbed state once that the pro-coagulant stimulus 
has been removed. 
 
Mechanical stimuli are of particular importance in the endothelium 
homeostasis. An increase in the blood flow enhances the hemodynamic 
forces acting on the vessel wall with the generation of the so-called shear 
and tensile stress. Shear stress is a tangential, frictional force acting in the 
direction of blood flow. As a consequence, shear stress involves only the 
surface of ECs, that will be gradually elongated in the direction of the flow37. 
At variance, tensile stress acts perpendicular to the vessel wall since it is the 
result of the dilating force of the blood pressure. Therefore, tensile stress 
involves not only ECs but also the other components of the vessel wall, that 
are fibroblasts and VSMCs. The activation of ECs by shear stress promotes 
the release of vasodilatant mediators (especially NO), whereas tensile stress 
directly stimulates VSMCs, thus inducing their contraction and EC stretching. 
Therefore, the net effect of mechanic stimuli on the vascular tone results 
from the interactions between the pressure-induced myogenic contraction 
and the endothelium-dependent vasodilatation induced by blood flow.  
 
In addition to the above-mentioned role in the regulation of blood 
coagulation, ECs also express cell surface-molecules that orchestrate the 
trafficking of circulating blood cells. These cell-associated molecules help 
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directing the migration of leukocytes into specific organs under physiologic 
conditions, and accelerate migration towards sites of inflammation. These 
pathways have been also implicated in platelet and erythrocyte adhesion in 
several common disorders associated with vascular occlusion32. 
 
2.2  Nitric oxide   
 
NO is a highly lipophilic free radical gas38 with an half-life of less than 5 
seconds38,39,40. It can easily diffuse from its source and reach its final 
targets - often localized at some distance from the sites of synthesis - by 
crossing  multiple cell membranes38.  
 
Experiments in isolated blood vessels and ECs suggest that the endothelial 
nitric oxide synthase (eNOS) (see below) is constitutively active and 
responsible for the so-called basal release of NO in the absence of evident 
external stimuli. When constitutively produced by the enzymatic action of 
eNOS, NO diffuses to the underlying  VSMCs where stimulates the guanylyl 
cyclase (GC) activity, thus resulting in vaso-relaxation and dilatation41. 
Moreover, NO also reduces the proliferation of VSMCs by preventing the 
release of their mitogen Platelet-Derived Growth Factor (PDGF). 
Other well-characterized actions of NO include the inhibition of leukocyte and 
platelet adhesion to the vascular wall, and the inhibition of platelet 
aggregation42. Importantly, NO also plays a crucial role in angiogenesis by 
promoting EC proliferation, differentiation, and migration to the perivascular 
space.  
 
The main mechanism responsible for NO effects on blood vessels   involves 
the activation of the soluble GC (sGC)-cGMP signaling pathway43,44 (Figure 
II). This pathway mediates the NO-dependent relaxation of VSMCs and the 
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suppression of platelet aggregation45. The affinity of sGC for NO is very high, 
thus allowing its activation also in the presence of nanomolar concentrations 
of NO46. Once activated, sGC catalyzes the conversion of guanosine 
triphosphate (GTP) to cGMP which in turn activates downstream effector 
systems such as protein kinases, phosphodiesterases, and ion channels47. In 
VSMCs, protein kinase G (PKG) is the main downstream target of cGMP. 
When activated by cGMP, PKG inhibits the release of calcium from the 
sarcoplasmic reticulum (SR) and its influx from the extracellular space. In 
addition, PKG also promotes the uptake of calcium by the SR and its 
extrusion through the membrane calcium-ATPase. As a result, intracellular 
calcium is reduced, and the calcium-dependent myosin light-chain kinase 
(MLCK) can no longer phosphorylate myosin, thus preventing the contractile 
process and favoring VSMC relaxation. To the maintenance of low levels of 
dephosphorylated myosin also contributes the direct effect of PKG on the 
regulatory subunit of the myosin light-chain phosphatase (MLCP).  
Also the antiaggregant effect of NO is mediated by cGMP via the reduction of 
platelet calcium levels and the negative modulation of molecules essential 
for platelet aggregation and activation, such as the glycoprotein IIb/IIIa38.  
 
Dysfunction of the sGC-cGMP pathway has been reported to contribute to 
the pathogenesis of many disorders, including hypertension and  
atherosclerosis48,49.  
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Figure II. NO and the sGC-cGMP pathway in the endothelium. Modified   
from Concepts in Biochemistry, Wiley 2002 
 
Another important signaling mechanism utilized by NO is S-nitrosylation 
where NO (or its metabolites) reacts with cysteine residues of target 
proteins38. S-nitrosylation has been shown to impact a wide range of 
biological processes including apoptosis, cellular trafficking, proliferation, NO 
synthase activity, ion channel activity and muscle contractility, transcription 
factor activity, protein secretion, blood flow, as well as a wide range of 
patho-physiological events50. In contrast to the sGC-cGMP pathway, 
nitrosylation requires micromolar concentrations of NO, thus allowing the 
nitrosylation of proteins localized in close proximity to the source of NO.  
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2.3 Nitric Oxide Synthase 
 
NO is synthesized by the catalytic action of enzymes termed NO Synthases 
(NOSs)38,51. It is produced from the terminal guanidine nitrogen of  L-
arginine and O2 through the formation of an NG-hydroxy-L-arginine 
intermediate yielding L-citrulline.  
 
There are three major isoforms of NOS, encoded by separate genes on 
separate chromosomes: neuronal NOS (nNOS), or type 1 NOS; inducible 
NOS (iNOS), or type 2 NOS; and endothelial NOS (eNOS), or type 3 NOS4. 
The three isoforms - that share approximately 50-60% sequence homology - 
have distinctive catalytic and regulatory properties, even if they show similar 
enzymatic and chemical properties. The common structure of NOSs contains 
two main domains (Figure III): (1) the N-terminus oxygenase domain, that 
exhibits homology with the other NOS isoforms and poor similarity with the 
cytocrome P450 mono-oxygenase enzymes; (2) the C-terminus reductase 
domain, that shows homology with various cytocrome P450 reductases. The 
N- and C-terminal domains are linked by a short sequence that binds 
calmodulin (CM), an allosteric modulator essential to reach full NOS activity. 
The N-terminus presents two binding sites: one for tetrahydrobiopterin 
(BH4) and heme, while the other one represents the active site where L-
arginine binds to the enzyme. On the other hand, the C-terminal domain 
binds the co-factors NADPH, FAD and FMN, which are all essential for NOS 
activity. Notably, the protein eNOS is synthesized as a monomer, but it has 
to form dimers to bind BH4 and L-arginine to generate NO (Figure III). In 
the absence of BH4 and L-arginine, the oxygenase domain of eNOS 
monomers generates superoxide anions instead of NO, a condition referred 
to as eNOS uncoupling (see below). 
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Figure III. The common structure of NOSs.  (A) NOS monomers transfer 
electrons from reduced NADPH to FAD and FMN, and possess a limited ability 
to reduce molecular oxygen to superoxide. Monomers and reductase 
domains can bind calmodulin (CaM) which enhances electron transfer inside 
the reductase domain. NOS monomers are unable to bind the cofactor BH4 
or the substrate L-arginine, thus monomers are not able to catalyze NO 
production. (B) In the presence of heme, NOS can form a functional dimer 
to produce NO. From  European Heart Journal (2011)  33, 829-837 
  
NOS enzymatic activity needs to be finely regulated to maintain NO 
homeostasis. A first level of regulation is represented by the tissue-specific 
expression of the different isoforms. nNOS is widely expressed in neurons of 
the central and peripheral nervous systems, but it is also found in skeletal 
muscle, the adventitial layer of some blood vessels, pulmonary epithelium, 
the gastrointestinal system, and the genitourinary system. iNOS was first 
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recognized in activated macrophages, but it has also been identified in 
various activated cell types, including monocytes, neutrophils, eosinophils, 
hepatocytes, VSMCs, myocytes, osteoblasts, fibroblasts, epithelium, and 
endothelium. eNOS is expressed in vascular endothelium as well as in blood 
platelets and cardiomyocytes53. 
 
Focusing on eNOS, its activity is controlled by a complex integration of 
transcriptional, post-transcriptional and posttranslational mechanisms38. For 
example, laminar shear stress modulates eNOS transcription through the 
activation of the transcription factor KLF2 or by the action of the Rho/Rho 
kinase pathway. The post-transcriptional level of regulation essentially 
regards mRNA stability. Although eNOS mRNA stability is notable under 
normal physiological conditions, it is diminished in the presence of oxidized 
low density lipoprotein (LDL), thrombin, inflammation, and hypoxia. The 
decrease in mRNA stability triggers a decrease in eNOS expression by 
maintaining at the same time a normal level of eNOS transcription.  
 
Post-translational mechanism(s) represent however the most important level 
of regulation of eNOS activity. The membrane targeting and recruitment of 
eNOS in caveolae are for example essential for this modulation. Caveolae 
are small invaginations of the plasma membrane enriched in proteins as well 
as in lipids - such as cholesterol and sphingolipids - that are involved in 
signal transduction54. In caveolae, eNOS interacts with the caveolae coating 
protein caveolin-1 (Cav-1). This protein-protein interaction inhibits eNOS 
activity by sterically occupy the calmodulin (CM) binding site. 
Mechanistically, the recruitment of CM to eNOS displaces Cav-1 from the 
enzyme thereby leading to its activation. CM is a key activator of eNOS that 
specifically links the enzyme activity to intracellular calcium levels. Elevation 
of intracellular calcium - or exposure of ECs to shear stress – promotes the 
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dissociation of the eNOS-Cav-1 complex, thus permitting the association of 
eNOS with the active calcium-CM complex. The caveolar targeting of eNOS is 
totally dependent on its co-translational myristoylation - the irreversible 
addition of a myristoyl group - at the N-terminal glycine55.  
eNOS is also subject to post-translational palmitoylation on two cysteine 
residues (Cys15 and Cys26). This modification is reversible and requires the 
prior N-myristoylation and membrane anchoring of eNOS. In particular, 
palmitoylations at Cys15 and Cys26 facilitate the hydrophobic interaction of 
eNOS with the caveolae, where it comes in close contact with regulatory 
molecules including G-protein–coupled receptors (GPCRs) and Akt. Hence, 
palmitoylation contributes not only to the proper localization of eNOS but 
also permits the integration of its activity with upstream signaling generated 
by neuro-humoral (agonists and hormones) and physical (shear stress) 
stimuli.  
 
A crucial level of post-translational regulation of eNOS activity is 
phosphorylation (Figure IV). Different sites of phosphorylation result in 
opposite effects on the enzyme activity: the phosphorylation of Ser1177 (in 
human) activates eNOS, while the phosphorylation of Thr495 inhibits it. 
Multiple kinases – such as the cAMP-activated protein kinase A (PKA), the 
phosphatidylinositol-3-kinase (PI3-K)/Akt pathway, the AMP-activated 
protein kinase (AMPK), the calcium-CM-dependent protein kinase II, and the 
extracellular regulated kinase 1/2 (ERK1/2) - are known to phosphorylate 
eNOS at Ser1177 in response to various stimuli (e.g., the vascular 
endothelial growth factor (VEGF), estrogens and shear stress). The 
phosphorylation of Ser1177 increases the electron flow and the affinity of 
eNOS for the calcium-CM complex56, thus increasing NO synthesis at lower 
levels of intracellular calcium. By contrast, Rho-kinase (e.g., in response to 
angiotensin II and thrombin), and protein kinase C (PKC) phosphorylate 
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eNOS at Thr495, thus inhibiting the enzyme. The activation of eNOS by 
phosphorylation at Ser1177 is facilitated by the concurrent 
dephosphorylation of Thr495.  
 
 
 
Figure IV. Regulation of eNOS activity by intracellular calcium and 
phosphorylation. An increase in intracellular Ca2+ leads to an enhanced 
binding of calmodulin (CaM) that facilitate the flow of electrons from NADPH 
(in the reductase domain) to the heme (in the oxygenase domain). The 
phosphorylation of Ser1177 increases the flux of electrons through the 
reductase domain, and finally the enzyme activity. Vice versa, the 
phosphorylation of Thr495 decreases the electron flux, and consequently the 
enzyme activity. Also PKC, the kinase that phosphorylates Thr495, and the 
protein phosphatase 1 (PP1), that dephosphorylates Thr495, are shown. 
From  European Heart Journal (2011)  33, 829-837  
 
Interestingly, eNOS is post-translationally regulated via S-nitrosylation by its 
product NO. S-nitrosylation mainly occurs on the enzyme localized in 
caveolae since the local hydrophobic environment favors the accumulation of 
NO and the formation of S-nitrosothiols. Only nitrosylation at the residues 
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Cys94 and Cys99 – that are located at the interface for dimer formation – 
results in eNOS inhibition. Importantly, S-nytrosilation is a reversible 
process, and denitrosylation of eNOS mainly occurs in the cytosol due to its 
high content of reduced thiols. 
 
Another possible mechanism for the post-translational regulation of eNOS is 
acetylation. Both acetylation of Lys610 and deacetylation of Lys497 and 
Lys507 increase eNOS enzymatic activity18. Oxidative stress (e.g., aging, 
hypertension, and diabetes) or an excessive intracellular level of NO (e.g., 
during inflammation) impair this regulatory process. 
 
Additional post-translational mechanisms of eNOS regulation are 
glycosylation -  the attachment of N-acetylglucosamine by O-linked N-
acetylglucosamine transferase at Ser1177, that blocks the activating 
phosphorylation of eNOS - and S-glutathionylation  - the addition of 
glutathione at Cys689 and Cys908, that favors the uncoupling of eNOS by 
promoting its reaction with oxygen and by preventing the binding of the co-
factors FAD and FMN18. 
 
2.4  Endothelial dysfunction 
 
The term endothelial dysfunction (ED) refers to broad alterations in the 
endothelial phenotype that contribute to the development and clinical 
expression of atherosclerosis and CVD57 (Figure V). The cardiovascular risk 
factors - including smoking, aging, hypercholesterolemia, hypertension, 
hyperglycemia - are all associated with alterations in endothelial function. 
ED finally leads to vessel malformation and regression, improper re-
vascularization, healing and regeneration, heart and brain ischemia, neuro-
degeneration, hypertension, preeclampsia, respiratory distress, and 
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osteoporosis58. Very importantly, ED is a reversible disorder, and strategies 
aiming at reducing cardiovascular risk factors - such as cholesterol lowering, 
antihypertensive therapy, smoking cessation, estrogen replacement therapy 
in postmenopausal women, and physical exercise - all induce an 
improvement in endothelial health, further supporting the proposed 
association between risk factors and ED. Moreover, the observation that 
pharmacological interventions that improve endothelial function are 
associated with a decrease in cardiovascular events supports the notion that 
cardiovascular risk factors share a common pathway that converges on ED. 
 
 
 
Figure 5. Processes of atherogenesis starting from endothelial dysfunction. 
From Nature Reviews Drug Discovery (2008) 7, 517-529 
 
The patho-physiology of ED is quite complex and involves multiple 
mechanisms. However, the earliest event in ED is a reduced release of NO 
coupled with an increase in Reactive Oxygen Species (ROS) in the vascular 
wall. The chronic production of ROS may exceed the capacity of cellular 
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enzymatic and non-enzymatic anti-oxidant systems, thus contributing to the 
onset of vascular disease.  
 
It is intriguing that eNOS, which normally helps to maintain the endothelium 
in a quiescent state, can switch to generate ROS instead of NO – the so-
called eNOS uncoupling - as part of the endothelial activation process. 
Currently, the deficiency of the cofactor BH4 has been associated to the 
production of superoxide anions. Again, the deficiency of L-arginine induces 
the eNOS-mediated formation of hydrogen peroxide59.  
 
An important source of cellular ROS are mitochondria, where superoxide -  
produced as a by-product of oxidative phosphorylation - were rapidly 
converted into molecular oxygen or hydrogen peroxide by the enzymatic 
activity of the mitochondrial superoxide dismutase (mSOD). Hydrogen 
peroxide is also a damaging ROS, but it is further degraded by other 
enzymes, such as catalase. The balance between the metabolic production of 
ROS and their degradation is altered in hypoxia or in pathological conditions 
characterized by hyperglycemia and increased circulating free fatty acids, 
such as obesity-related metabolic disorder and type II diabetes. Another 
important source of metabolic ROS is xanthine oxidase (XO), an enzyme that 
generates ROS as a by-product of the purine catabolism. Finally, endothelial 
ROS may also be induced by external stimuli - such as inflammatory 
cytokines and growth factors - and by the interaction of the endothelium 
with leukocytes.  
Regardless of their source, the interaction between ROS and NO sets up a 
vicious circle, which contributes to EC activation and inflammation. In fact, 
ROS – hydrogen peroxide, specifically – reacts with NO to form 
peroxynitrite, an oxidant and nitrating molecule that can damage a wide 
array of cellular molecules. In particular, peroxynitrite is involved in the 
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formation of the oxidized LDL (oxLDL) that crucially contributes to EC 
activation and dysfunction60. The binding of OxLDL to its main receptor LOX-
1 supports the recruitment of circulating leukocytes, triggers foam cell 
formation, sustains migration and proliferation of VSMCs, and reduces NO 
bioavailability via dephosphorylation of the activating Ser1177 on eNOS61. 
Furthermore, OxLDL-LOX-1 interaction may also contribute to plaque 
destabilization by inducing VSMC apoptosis and the release of matrix 
degrading enzymes (MMPs). 
 
ED could be considered to a some extent a kind of endothelial activation, in 
which ECs switch from a quiescent to an activated phenotype where the 
stimulation of various molecular machineries results in the expression of 
chemokines, cytokines, and adhesion molecules. As a matter of fact, the 
dysfunctioning endothelium, in concert with NO deficiency, produces some 
other substances and mediators that are detrimental to the vessel wall, such 
as for example thromboxane A2 (a pro-thrombotic agent, TXA2), and 
prostaglandin H2 (a potent vasoconstrictor, and also the precursor of TXA2). 
Up-regulation of adhesion molecules, generation of chemokines, and 
production of the plasminogen activator inhibitor-1 (PAI-1) – an inhibitor of 
the tissue plasminogen activator (tPA) and urokinase (UPA) that are required 
for the breakdown of blood clots – also participate to the establishment of 
the inflammatory and pro-thrombotic state of the activated endothelium. 
Vasoactive peptides, such as angiotensin-II and endothelin-1, ADMA 
accumulation, hypercholesterolemia, hyper-homocysteinemia, an altered 
insulin signaling, and hyperglycemia also contribute to the onset of ED. 
Among vasoactive peptides, an important element involved in ED is 
Endothelin-1 (ET-1). ET-1 is the strongest vasoconstrictor molecule of 
endothelial origin, and acts through the binding to its specific receptors ETA 
and ETB. ETA are expressed only on VSMCs and cause vasoconstriction and 
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cellular proliferation, while ETB are localized both on VSMCs and ECs, and 
induce vasodilatation by stimulating NO production, which in turn acts as a 
negative feedback on ET-1 production. When NO bioavailability is reduced, 
the negative feedback is compromised, and consequently the vasoconstrictor 
effect of ET-1 become predominant. 
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3.  Estrogens and the cardiovascular system 
 
Several clinical and epidemiological data support a central role for estrogens 
in cardiovascular physiology and disease, especially in relationship to the 
described premenopausal gender differences. 
 
The effects of estrogens are mediated by both genomic and non-genomic 
mechanisms involving the regulation of target gene expression and the 
activation of non-transcriptional signaling pathways, respectively (Figure 
VI).  There are two different isoforms of nuclear estrogen receptors (nERs), 
usually referred to as ERα and ERβ, that showed a significant overall 
sequence homology. Estrogens bind to the C-terminal E domain, and the 
resulting estrogen-ER complex undergoes dimerization, translocation to the 
nucleus, and binding to the estrogen response element (ERE) on target 
genes via the DNA-binding domain C62. Mouse knock out studies have shown 
that the expression of ERα is required for the protective effect of 17β 
estradiol (E2, the active, natural form of estrogen) against pathologic 
vascular injury responses and atherosclerosis. At variance, ERβ seems to be 
dispensable for these effects even if the ERβ-deficient mice are hypertensive 
when compared to wild-type animals38.  
 
It has also been shown that E2 reduces the production of inflammatory 
cytokines and neutrophil adhesion in injured vessels, although it is unknown 
if these effects require nER. At the cellular level, E2 inhibits VSMC 
proliferation - a central patho-physiologic component of the adverse vascular 
remodeling in response to injury -  and promotes the proliferation and 
migration of ECs – a crucial aspect of vascular repair after injury.  
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Figure 6. Genomic and non genomic estrogen signaling pathways. E2 
activates nERs by inducing receptor dimerization and direct binding to the 
promoters of target genes, or modulation of other transcription factors 
through protein-protein interaction. At the plasma membrane, a 
subpopulation of ERs interacts with adaptor protein and signaling molecules 
to mediate rapid signaling via PI3K-Akt and MAPK pathways. E2, or the  
agonists G-1, also activates GPER that stimulates cAMP production, calcium 
mobilization and c-Src. The activation of c-Src is in turn responsible for the 
trans-activation of EGFR, which finally activates MAPK and PI3K-Akt 
pathways to induce genomic or rapid non-genomic effects. From Nature 
Reviews Endocrinology (2011) 7, 715-726 
 
A small subpopulations of ERα is palmitoylated and localized at the plasma 
membrane where it forms signaling complexes in caveolae. These 
membrane-bound ERα elicit rapid non-genomic effects, leading to the 
activation of several signal transduction pathways, including c-Src, PI3-K-
Akt and ERK1/2, through the interaction with specific adaptor proteins. One 
of the best characterized non-genomic effects of the membrane ERα is the 
fast activation of eNOS in ECs, resulting in NO formation and vasorelaxation.  
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Very recently, it has been proposed that rapid signaling through ERα is also 
essential for many of the transcriptional responses of ECs to E2, and that the 
ERα rapid signaling may be critical for the in vivo vasculo-protective and 
anti-inflammatory effects of estrogen63. 
 
It has been recently reported that a G protein-coupled receptor named 
GPR30/GPER (G protein–coupled estrogen receptor) may also contribute to 
estrogenic effects64. This receptor is physically associated with Gαs, and 
formation of cAMP is measured following stimulation with estrogen.  
Moreover, GPER promotes estrogen-mediated trans activation of the 
epidermal growth factor receptor (EGFR)-to-ERK1/2 signaling axis via a βγ-
dependent mechanism. GPER is expressed in the vascular endothelium, and  
its stimulation induces eNOS phosphorylation and activation65. To the GPER-
dependent vasodilatory effects also contribute the reduction of 
vasoconstrictor-induced changes in intracellular calcium and the inhibition of 
VSMC proliferation. Collectively, these findings support the hypothesis that 
GPER activation may dilate blood vessels by stimulating eNOS and inhibiting 
the proliferation and migration of VSMCs. A role for GPER in vasorelaxation 
is further sustain by the finding that aged female mice express reduced 
levels of GPER in their mesenteric arteries, and show a decrease in the 
vasodilatation induced by the GPER agonist G166.  
Interestingly, GPER is strongly expressed in cardiac tissue67, and several 
studies demonstrate its cardioprotective properties. Namely, GPER activation 
– as well as membrane ERs - limits ventricular remodeling and hypertrophy 
following heart attack and ischemia/reperfusion injury in preclinical models 
of myocardial infarction64. 
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4.  Angiogenesis  
 
The term angiogenesis refers to the formation of new blood vessels from the 
existing ones, in opposition to vasculogenesis which is the de novo formation 
of vessels during embryogenesis68. 
 
Angiogenesis is mainly needed for the embryonic development and 
contributes to the growth of organs after birth. In the adult, vessels are 
quiescent for most of the time, and only rarely form new branches, since 
ECs are under the control of a finely tuned balance of stimulatory and 
inhibitory factors, including growth factors, angiopoietins, chemokines, 
integrins, junctional molecules, oxygen sensors, and endogenous inhibitors. 
However, ECs retain high plasticity, and during adulthood, angiogenesis 
normally occurs in selected phases of the female reproductive cycle, in the 
placenta during pregnancy, and in the wound healing repair process58. 
Beside physiological angiogenesis, a dysregulated angiogenic signaling leads 
to an uncontrolled vessel growth that contributes to the pathogenesis of 
many disorders. Pathological angiogenesis is associated with inflammatory 
disorders, blindness, asthma, atherosclerosis, infectious diseases (e.g., 
AIDS), diabetes, cirrhosis, endometriosis, autoimmune disease and cancer58. 
 
4.1 Basic aspects of angiogenesis 
 
Angiogenesis is a multi-step process that strictly depends on directed 
migration and proliferation of ECs. Both the processes are controlled by 
VEGF-A, the main growth factor acting on ECs69. When the balance between 
pro- and anti-angiogenic factors is altered - i.e. the angiogenic switch, 
induced for example by hypoxia – VEGF is secreted by many types of 
parenchymal cells, and binds to its tyrosine kinase receptor 2 (VEGFR2) on 
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still quiescent ECs. As a consequence of the activation of the VEGFR2 
signaling, stimulated ECs adopt a migrating “tip” cell behavior at the 
forefront of the vessel sprout (Figure VII). Long, thin cellular processes 
emerging from tip cells and called filopodia extend into the environment and 
secrete large amounts of proteolytic enzymes, which digest the extracellular 
matrix (ECM) to develop the sprout. When an adequate number of filopodia 
has anchored tip cells to the substratum, the contraction of actin filaments 
within filopodia themselves pulls tip cells toward the VEGF stimulus. 
Importantly, tip cell filopodia express high levels of VEGFR2, and “sense” 
differences in VEGF concentration, thus permitting EC migration and 
alignment all along the VEGF gradient. In the meantime, VEGF stimulates tip 
cells to produce Delta-like-4 (Dll4) - a trans-membrane ligand for Notch 
receptors - that interacts with Notch1 receptors on the adjacent ECs. The 
activation of the Dll4-Notch pathway leads to the down-regulation of VEGFR2 
in those cells, thus creating a situation in which neighboring cells express 
different levels of VEGFR2, and in turn different responsiveness to VEGF70. 
In addition, Notch receptor signaling also drives a greater expression of 
VEGFR1 - a high-affinity and low-activity receptor that acts as a competitive 
inhibitor of VEGF signaling - further increasing the gap in VEGF response 
between adjacent cells. The cell expressing VEGFR2 and Dll4 is a non-
proliferative tip cell while the Notch-expressing neighbors of the tip cell 
become a proliferative stalk cell that contributes to the elongation of the 
nascent sprout (Figure VII). These stalk cells finally lumenize to form a 
functional blood vessel. The recruitment of pericytes and the deposition of 
ECM are last steps for the complete maturation and stabilization of vessels. 
Tip/stalk specification is a highly dynamic process in which cells undergo  a 
continue transition between tip and stalk identities through all the growth of 
the vessel. However, cells with the highest VEGFR2/VEGFR1 expression ratio 
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– and thus the highest VEGF responsiveness - are always at the tip of the 
new sprout.   
It has been recently demonstrated that also the VEGF-C–VEGFR3 signaling 
pathway controls the branching morphogenesis of blood vessels70. 
Interestingly, VEGFR3 is expressed at a high level in endothelial tip cells, 
while its ligand VEGF-C is mainly secreted by macrophages localized to 
vessel branch points. 
 
 
 
Figure VII. Branching morphogenesis a) Parenchymal cells up-regulate 
VEGF production. b) ECs exposed to VEGF gradient are induced to migrate 
becoming a future tip cell. c) The tip cell obtains its leading position in the 
growing sprout, and inhibits its neighbors ECs. d) VEGFR2 activation leads 
to up-regulation of the Notch ligand Dll4 on the tip cell. Dll4 in turn activates 
Notch in the neighboring cell, resulting in up-regulation of VEGFR1 and 
inhibition of VEGFR2 on the neighboring cell that adopt a stalk phenotype. 
Modified from Nat Rev Clin Oncol (2009) 6, 315-326. 
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The capability of ECs to rapidly switch from a quiescent state to a highly 
migratory and proliferative state during vessel sprouting is mainly regulated 
by the VEGF/VEGFR2 and Dll4/Notch axis. But it has recently been proposed 
that another crucial level of branching regulation is cellular metabolism that 
may drive vessel sprouting through a metabolic switch. It is well-known that 
ECs do not rely on oxidative metabolism for ATP production but are highly 
glycolytic cells, i.e. generate more than 80% of their ATP by aerobic 
glycolysis71. Moreover, ECs further increase their glycolytic flux when pass 
from the quiescent to the activated phenotype. In addition, silencing of the 
enzyme phosphofructokinase-2/fructose-2,6-bisphosphatase 3 (PFKFB3) - 
which stimulates glycolysis - impairs EC proliferation, migration, and 
vascular sprouting in vitro, and  the genetic deficiency of PFKFB3 in ECs 
causes vascular hypobranching in mice71. All these results auggest a central 
regulatory role for  glycolysis in vessel branching. 
 
In addition to glycolysis, also fatty acid (FA) metabolism contribute to 
angiogenesis. It has been reported that ECs, in the absence of glucose, 
increase FA oxidation (FAO) flux in an AMPK–dependent manner to 
compensate for the lack in glycolytic ATP production72. FAO is therefore a 
critical bio-energetic supply pathway for ECs, especially when the availability 
of glucose is reduced73,74. Recently, it has also been shown that reduction of 
FAO impairs de novo nucleotide synthesis for DNA replication in ECs. In this 
manner, FAO selectively regulates EC proliferation, suggesting that distinct 
metabolic pathways may control distinct EC functions during vessel 
sprouting75.  
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4.2 Therapeutic aspects of angiogenesis 
 
4.2.1 Antiangiogenic therapy 
 
Angiogenesis is a hallmark of cancer development that has long been 
considered an attractive therapeutic target. The signaling molecule VEGF 
plays a central role in the formation of blood vessels and is frequently highly 
expressed and secreted by tumor cells. Thus, clinical efforts to develop 
antiangiogenic therapies have largely focused on inhibiting VEGF, and several 
VEGF blockers – such as for example bevacizumab, a VEGF-neutralizing 
antibody - have been developed and authorized for medical use. However, 
the clinical efficacy of VEGF inhibitors is lower than that observed in 
preclinical cancer models. Furthermore, the efficacy of antiangiogenic 
therapies differs among cancer types. In general, antiangiogenic drugs are 
more efficient in well-vascularized tumors (e.g., clear cell renal cancer), and 
less effective in poor vascularized cancers (e.g., pancreatic adenocarcinoma 
and gastric cancer). Additionally, VEGF blockade show promising effects in 
neo-adjuvant trials, but largely negative results have been obtained in the 
adjuvant setting. Nonetheless, the USA Food and Drug Administration (FDA) 
and the European Medicines Agency (EMA) have approved the use of 
bevacizumab – in combination with classic chemotherapic drugs - in 
metastatic colorectal cancer, glioblastoma (GBM), non-squamous non-small 
cell lung carcinoma (NSCLC), metastatic renal cell carcinoma, and persistent, 
recurrent, or metastatic carcinoma of the cervix. Treatment with VEGF 
inhibitors combined with chemotherapy generally prolongs the overall and 
progression-free survival of responsive cancers patients. Unfortunately, the 
benefit is generally limited to a few months76. 
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4.2.2 Therapeutic angiogenesis 
 
The stimulation of angiogenesis may be a successful therapeutic approach in 
vascular insufficiency or ischemia where the goal is bypassing diseased or 
occluded vessels to enhance the development of compensative collateral 
vascular circuits77. Again, VEGF is in the focus, along with fibroblast growth 
factor (FGF) that is also involved in the control of vessel formation and 
differentiation. The therapeutic angiogenesis approach is supported by an 
impressive body of preclinical evidence that demonstrate significant 
improvements in blood flow, re-vascularisation, and myocardial function 
after angiogenic cytokine delivery in different animal models of myocardial 
and limb ischemic disease. But larger trials are needed to translate pre-
clinical results into an established benefit for patients.  
 
Different ways have been tested to promote therapeutic angiogenesis. The 
first example is protein therapy, that implies the direct use of growth factor 
proteins, mainly VEGF and FGF. Conflicting outcomes have however been 
reported in the literature on the VIVA (VEGF in Ischemia for Vascular 
Angiogenesis) therapy - that relies on the intracoronary and intravenous 
recombinant human VEGF-A infusion - and on the intracoronary infusion of 
basic FGF (bFGF or FGF-2). Critical topics are the short serum half-life of 
these proteins and the requirement of high doses and of their frequent 
administration. Overall, the results of clinical trials of angiogenic cytokine 
protein treatment were disappointing 
 
Gene therapy is an alternative way of delivering therapeutic cytokines to 
achieve a more sustained therapeutic effect after a single application. Gene 
therapy abolishes the requirement for repeated administrations of short-
lived proteins, and reduces risks correlated to systemic exposure at high 
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concentrations of cytokines. Preclinical studies on VEGF and FGF gene 
delivery by using plasmid or adenoviral vectors have been shown notable 
improvements in heart function and perfusion in different animal models of 
myocardial ischemia77. But, again, most of the phase II/III trials of 
therapeutic angiogenesis using plasmid vectors in coronary artery or 
peripheral arterial disease have yielded negative results. The delivery of 
VEGF by adenoviruses - that display a high transduction efficiency in ECs 
and VSMCs, and that can transduce quiescent, non-proliferating cells – also 
failed to demonstrate any improvement in peak walking time, or in other 
measures of the quality of life, in a phase II trial engaging 105 patients.  
 
Other alternative approaches could be combination therapies (e.g., VEGF 
plus angiopoietin or FGF), or delivery via stem cells. Studies in animal 
models suggest that bone marrow-derived or circulating endothelial 
progenitor cells (EPC) promote endothelial regeneration in arterial injury and 
collateral angiogenesis in the ischaemic heart78.   
 
Collectively, the lack of significant therapeutic effects in trials based on 
angiogenic cytokine treatments is probably due to the failure of existing 
approaches. Progress in the bench-to-bedside will permit advances in the 
delivery, expression, and biological efficacy of pro-angiogenic therapies. 
  
Aims of the project  
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An impaired endothelial function represents the first step in the onset and 
development of cardiovascular disease (CVD). It has been demonstrated that 
CVD is less prevalent in women than men until midlife, and the female 
advantage has been attributed to estrogens, which are lost with menopause. 
Although these well-established epidemiological and clinical data, very little is 
known about innate sex properties of male and female endothelial cells (ECs). 
 
In the present study, we investigated the in vitro properties of human primary 
male and female ECs. To this aim, we used human umbilical vein ECs (HUVECs) 
deriving from pooled male and female newborn donors. We started by searching 
for an involvement of hormones – in particular estrogens - and of other 
biological active molecules in male and female EC behavior. Then, in view of the 
importance of nitric oxide (NO) in the EC physiology, we focused on the 
contribution of eNOS - the enzyme responsible for its formation - to the 
proliferation, migration, and in vitro angiogenesis of male and female ECs.  
 
Knowledge of the molecular mechanism(s) underlying sex-based differences in 
male and female EC behavior might have important implications for 
understanding the difference in the onset and development of CVD in men and 
women. Furthermore, these knowledge could be helpful to the development of 
novel sex-oriented strategies for drug therapies.  
 
 
 
  
Results
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Metabolic activity in male and female HUVECs 
To identify putative differences in metabolic properties of male and female 
HUVECs (abbreviated as M-ECs and F-ECs, respectively), we first compared their 
ability of reducing MTT and WST-8 through cellular NAD(P)H-dependent oxido-
reductase enzymes. Results are shown in Fig. 1, and demonstrated that no 
significant differences were detectable between F-ECs and M-ECs (MTT, Fig. 1A; 
WST-8, Fig. 1B). Similarly, F-ECs and M-ECs contained super imposable 
amounts of total cellular ATP (Fig. 1C). It is well-known that ECs are highly 
dependent on aerobic glycolysis for energy production71. We therefore compared 
the effects of the glycolytic inhibitor 2-deoxyglucose (2-DG, 20 mM) and of the 
mitochondrial electron transport chain blocker rotenone (1 µM) on the total 
cellular ATP content in F-ECs and M-ECS. We found that ATP levels are equally 
blunted in the presence of 2-DG showing percentages of inhibition of about 80% 
in both F-ECs and M-ECs (Fig. 1D).  As expected, rotenone weakly reduced ATP 
levels (by about 20%), but its effect is again similar in cells of both sexes (Fig. 
1D). These results confirm the dependence on glycolysis and the restricted 
contribute of oxidative phosphorylation to ATP generation in ECs, showing for the 
first time that these bio-energetic requirements are similar for F-ECs and M-ECs. 
 
Hormone deprivation induces a decrease in metabolic activity and cell 
number in F-ECs and M-ECs  
A crucial issue in endothelial patho-physiology concerns estrogens and their 
involvement in the sex-related incidence of cardiovascular pathologies11,13. To 
study the contribution of estrogens to in vitro EC behavior, we set up some pilot 
experiments to compare metabolic activities of F-ECs and M-ECs grown in a 
Standard Medium (199 medium w/phenol red supplemented with normal FBS, 
SM) or in a nominally estrogen-free medium (199 medium w/out phenol red 
supplemented with charcoal-stripped FBS, CS-FBS) commonly used for in vitro 
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studies on hormone activities. We refer to this last medium as Charcoal Medium 
w/out phenol red (ChM w/out phenol red). F-ECs and M-ECs were cultured for 
48h in SM or ChM w/out phenol red, then fresh media were added, and 
metabolic activities were measured after a further 48h-incubation. In the 
absence of estrogens, MTT absorbance (Fig. 2A) and ATP levels (Fig. 2B) were 
significantly reduced in comparison to SM in ECs of both sexes. To elucidate if 
decreases in MTT and ATP were merely dependent on a failure in metabolic 
activity, or were vice versa consequent to a reduced cell growth, the number of 
F-ECs and M-ECS was measured, and a significant reduction was found in cells 
cultured in ChM w/out phenol red (Fig. 2C). Again, no differences emerge 
between F-ECs and M-ECs in the antiproliferative effects induced by the 
nominally estrogen-free medium. 
 
Sex hormones did not prevent the decrease in metabolic activity and cell 
number induced by hormone deprivation in F-ECs and M-ECs 
By using an add-back approach, we tested if estrogens were able to counteract 
the inhibitory effects observed in F-ECs and M-ECs cultured in ChM w/out phenol 
red. The addition of a physiological concentration of 17-β2 estradiol (E2, 1 nM) - 
or its vehicle (ethanol) - for the last 48h of incubation left unaffected the ChM-
induced decrease in MTT absorbance (Fig. 3A). Super imposable results were 
obtained by measuring the total cellular ATP (Fig. 3B) and the number of cells 
(Fig. 3C). Since the stripping procedure removes sex hormones other than E2 
from serum, we checked the effect of ChM supplementation with 
dihydrotestosterone (DHT, 1 nM), and found that it did not prevent the decrease 
in MTT absorbance (Fig. 3D). Likewise, the simultaneous addition of E2 and DHT 
(both at 1 nM concentration) left unaffected the reduced MTT absorbance (Fig. 
3D). Also the treatment with higher concentrations of E2 and/or DHT (10 nM) 
did not modify these results (data not shown). All together, these results 
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demonstrate that ECs of both sexes underwent a comparable and significant 
decrease in cell number - and consequently in metabolic activity - without any 
apparent cell death when cultured in a phenol red-free medium supplemented 
with CS-FBS. Importantly, this reduction was independent of the presence of E2 
and/or DHT regardless of the described expression of their receptors in both F-
ECs and M-ECs30.  
 
CS-FBS is responsible for the decreased metabolic activity and cell 
number in F-ECs and M-ECs 
Our results suggest that the decrease in metabolic activity and cell number 
observed in both male and female ECs cultured in ChM w/out phenol red was not 
related to the lack of sex hormones. Moreover, since ECs cultured in 199 
medium w/out phenol red supplemented with normal FBS (SM w/out phenol red) 
did not show any difference in MTT absorbance when compared to ECs grown in 
SM (Fig. 4A), we excluded the involvement of phenol red and of its estrogenic 
properties79. Consequently, we focused our attention on FBS by comparing cells 
grown in SM with cells cultured in 199 medium containing phenol red and CS-
FBS. We refer to this medium as Charcoal Medium (ChM). Importantly, we 
submit to the stripping procedure exactly the same lot of serum present in SM. 
Therefore, in this experimental setting, F-ECs and M-ECs were exposed to 
growth media that differ only for FBS components.  The presence of CS-FBS was 
sufficient to induce a significant decrease in MTT absorbance (Fig. 4B) and cell 
number (Fig. 4C). Again, the addition of E2 (1 nM) did not revert the loss in MTT 
and ATP induced by CS-FBS in F-ECs (Fig. 4D) and in M-ECs (data not shown). 
At variance, F-ECs and M-ECs were able to fully recover their metabolic activity 
when SM was added instead of hormones (Fig. 4E), thus confirming that one or 
more substances removed from FBS by stripping procedure, and different from 
sex hormones, are crucially required for HUVEC growth. Again, no differences 
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were observed between F-ECs and M-ECs, favoring the suggestion that the FBS 
component(s) lost in CS-FBS owns wide implications in EC physiology.   
 
Thyroid hormone does not prevent the decrease in metabolic activity 
and cell number in F-ECs and M-ECs 
The stripping procedure reduces or depletes the serum concentration of many 
biologically active substances such as steroids, thyroid and peptide hormones, 
vitamins, electrolytes, enzymes, metabolites, and lipids80,81. Among hormones, 
thyroid hormone (TH, 3,5,3′-triiodo-l-thyronine, T3) plays a central role in the 
regulation of angiogenesis by acting through multiple genomic and non-genomic 
mechanisms82. We therefore tested the effect of its addition by using the add-
back approach described above for sex hormones. The treatment with T3 (10 
nM) was not able to prevent the inhibitory effects on MTT absorbance (Fig. 5A) 
and cell number (Fig. 5B) in both F-ECs and M-ECs, thus suggesting that T3 
does not represent the substance lost in CS-FBS crucially required for EC growth. 
 
CS-FBS impairs in vitro angiogenesis  
Among growth factors, Vascular Endothelial Growth Factor (VEGF) and basic 
Fibroblast Growth Factor (bFGF) are critically involved in EC physiology, being 
able to induce their growth, migration and in vitro differentiation69. We therefore 
tested if VEGF (20 ng/ml) and bFGF (20 ng/ml) were able to revert the inhibitory 
effect of CS-FBS. The decrease in MTT was maintained in the presence of the 
growth factors (Fig. 6A), thus demonstrating that neither VEGF nor bFGF were 
the substance(s) lost in CS-FBS essential for EC growth. Furthermore, we set up 
a 3-D assay by embedding size- and cell number-defined HUVEC spheroids in a 
collagen gel to study in vitro angiogenesis83,84. In this assay, spheroids from F-
ECs (Fig. 6B, left panel) and M-ECs (data not shown) totally retained their 
ability to sprout when suspended in SM. At variance, the outgrowth of capillary-
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like structures was significantly reduced when spheroids were suspended in ChM 
(Figs. 6B, right panel, and 6C for quantification). Interestingly, the decrease in 
sprouting was more marked in spheroids from M-ECs, even if the basal capillary 
outgrowth was fully comparable between the two sexes (Fig. 6C). These results 
demonstrated that a crucial feature of ECs, i.e. their ability to undergo in vitro 
angiogenesis, is missed when they are cultured in CS-FBS. 
 
Acetate and palmitic acid partially restore in vitro angiogenic 
phenotypes impaired by CS-FBS in F-ECs and M-ECs  
Beside hormones and peptides, charcoal stripping also deprives serum of fatty 
acids (FAs)85, thus limiting the ability of ECs cultured in CS-FBS to undergo FA 
oxidation (FAO). Since metabolic pathways are emerging as important regulators 
of angiogenesis72, and especially FAO has been reported to be crucially involved 
in the regulation of EC proliferation75, we focused our attention on FAs to 
investigate if their defeat in CS-FBS might be responsible for the alterations in 
the EC behavior that we observed. To this purpose, we set up reconstitution 
experiments by adding sodium acetate – that is metabolized to acetyl-CoA, thus 
substituting for the depleted FAO-derived acetyl-CoA – or palmitic acid to F-ECs 
and M-ECS cultured in ChM.  We found that the presence of acetate (20 mM) or 
palmitic acid (250 µM) was able to prevent the loss in cell number induced by 
ChM in both F-ECs (Fig. 7A) and M-ECs (Fig. 7B). Since acetate and palmitic 
acid reverted the number of ECs to about the 75% of the number measured in 
control conditions, we also added E2 to test if its presence was able to fully 
restore the proliferative capability of ECs. But the addition of E2 (1 nM) did not 
further improve the recovery induced by acetate or palmitic acid (Figs. 7C and 
7D, respectively). More importantly, spheroids from both F-ECs and M-ECs 
partially restored their ability to sprout in the 3-D spheroid assay when acetate 
(20 mM) or palmitic acid (250 µM) were added to ChM (Figs. 7E and 7F, 
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respectively). The addition of palmitic acid reverted the cumulative sprouting to 
about the 50% of the sprouting measured in control spheroids both in F-ECs and 
M-ECs. At variance, acetate apparently reversed sprouting less efficiently in M-
ECs than in F-ECs (30% vs 70% of the control sprouting, respectively). However, 
when results were expressed as fold-over-ChM, acetate reversed sprouting by 
about 2-fold in F-ECs and 4-fold in M-ECs, due the more marked decrease in  
sprouting showed by M-ECs. These results suggest that the lack of FAs is 
involved in the reduced proliferation and sprouting observed in ECs cultured in 
the CS-FBS containing medium. Once more, differences between F-ECs and M-
ECs were not so evident, with the exception of a higher sensitivity of M-EC 
sprouting to the loss of FAs. 
 
The expression of eNOS is higher in F-ECs than in M-ECs 
Cardiovascular risk factors are all associated with alterations in endothelial 
function that are triggered by a loss in NO production as the consequence of a 
reduced eNOS activity.  For this reason, it is crucial to investigate if differences 
in the eNOS availability exist between F-ECs and M-ECs. We started our 
experiments by analyzing eNOS expression, confirming our previous results30 in 
another set of donors. The eNOS protein expression was about 2-fold higher in 
F-ECs than in M-ECs (Fig. 8A), and a comparable increase was observed at the 
mRNA level (Fig. 8B). To better characterize this diversity, we performed 
western blots on ECs obtained from male and female twin umbilical cords, 
showing that the different eNOS expression between M-ECs and F-ECs was 
conserved (Fig. 8C). Moreover, the relative higher amount of eNOS found in F-
ECs was already present when HUVECs of both sexes were immediately lysed 
after the flushing from male and female twin umbilical cords i.e. without any in 
vitro passage (Fig. 8D). These results suggest that the improved eNOS 
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expression might be a typical feature of F-ECs, already present at birth, and not 
acquired during the in vitro culture of cells.  
To explore the functional status of eNOS, we investigated the dimer-to-monomer 
ratio in F-ECs and M-ECs.  Monomeric (130 kD) and dimeric (260 kD) forms of 
eNOS have been described in various tissues and cells, and the formation and 
stability of dimers are critically required for the enzyme to functionally produce 
NO42. We found a significant increase in the dimer-to-monomer ratio in F-ECs 
compared to M-ECs (Fig. 8E), suggestive of a correlation between the 
expression of eNOS and the amount of functional enzyme in ECs.  
 
eNOS is not involved in the control of M-EC and F-EC proliferation  
To find a biological significance for the increased female expression of eNOS, we 
first compared proliferative properties of M-ECs and F-Cs, and their dependence 
on eNOS activity by using L-NAME, a well-known NOS inhibitor. We did not 
observe any difference in the growth rates of M-ECs and F-ECs (Fig. 9A) that 
showed totally overlapped doubling times (47.5±5.4 and 47.6±6.0 h for M-ECs 
and F-ECs, respectively). The addition of L-NAME (100 µM) did not modify 
proliferation at any time tested neither in M-ECs nor in F-ECs (Fig. 9B).  
 
A different role for eNOS in the control of M-EC and F-EC migration 
Having excluded the involvement of eNOS in EC proliferation, we analyzed its 
contribute to migration, another crucial event characterizing EC phenotype. M-EC 
and F-EC migration was initially evaluated in a chemotaxis assay using FBS as 
attractant factor. In this assay, F-ECs showed a greater migratory capability in 
comparison to M-ECs (Fig. 10A), and the presence of L-NAME (100 µM) 
inhibited the chemotactic response in cells of both sexes (Fig. 10B). However, 
when the percent of L-NAME-induced inhibition was calculated, it resulted 
significantly higher in F-ECs than in M-ECs (32.6±3.0% vs 15.7±1.9%, 
respectively) (Fig. 10C).  
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Migration was also studied by using a 2-dimensional (2-D) wound healing test. 
In this assay, we did not observe any difference in the percent of wound closure 
– measured 15h after the scratch - between control M-ECs and F-ECs (60.2±3.0 
and 56.7±4.1%, respectively) (Figs 11A, and 11B for quantification). But, 
again, the addition of L-NAME (100 µM) was more effective in inhibiting the 
percent of wound closure in F-ECs than in M-ECs. Indeed, the ability to close the 
wound was reduced by 80% in L-NAME-treated F-ECs, and only by 20% in M-
ECs, in comparison to the corresponding control cells (Fig. 11B).  
To test if the effect of L-NAME was attributable to its ability of specifically 
inhibiting eNOS activity, the expression of the enzyme was silenced by using 
siRNA, and 48h after transfection a scratch assay was performed. The knock-
down of eNOS reduced by about 50% the percent of wound closure in F-ECs 
whereas it left unaffected the capacity of M-ECs to close the wound (Fig. 11C). 
A representative blot showing the ability of siRNA to totally silence eNOS 
expression is shown in Fig. 11D.  
 
M-ECs strictly depend on proliferation to close the wound  
Wound healing is the result of a complex process which relies on both cell 
migration and proliferation. To extrapolate the contribution of cell growth to the 
closure of in vitro wounds, we performed the scratch assay on M-ECs and F-ECs 
mitotically arrested by the addition of the antibiotic mitomycin (500 ng/ml). 
Surprisingly, M-ECs became unable to close the wound when proliferation is 
blocked by mitomycin (Fig. 12A). At variance, the proliferative break did not 
affect the ability of F-ECs to close the gap (Fig. 12A). Indeed, the percent of 
wound closure was reduced by about 85% in mitomycin-treated M-ECs, while it 
remained unchanged in growth-arrested F-ECs (Fig. 12B).  
Importantly, migration and proliferation seem to be regulated through 
independent pathways. In fact, the simultaneous addition of L-NAME (100 µM) 
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and mitomycin (500 ng/ml) induced an inhibition in the percent of gap closure 
that did not significantly differ from the maximal reduction induced by mitomycin 
or L-NAME alone, in M-ECs and F-ECs, respectively (Figs. 13A and 13B).  
 
Collectively, all the results shown in Figs. 10-13 suggest that the ability to 
migrate and to close the wound significantly differs in their dependence on eNOS 
activity between M-ECs and F-ECs. The activity of eNOS seems to be a crucial 
requirement in F-ECs while M-ECs show a more relevant dependence on 
proliferation.  
 
eNOS is essential for in vitro angiogenesis in F-ECs  
Angiogenesis is the result of a coordinated process where the growth of new 
blood vessels relies not only on the migration of specialized cells at the forefront 
of vascular sprouts – the tip cells – but also on trailing cells that undergo 
proliferation to elongate the branch – the stalk cells70. Therefore, we set up a 3-
D spheroid assay that recapitulates in vitro the angiogenic process83,84. In this 
assay, spheroids from M-ECs and F-ECs undergo sprouting in a 3-D collagen 
matrix as the result of the migratory and proliferative contribute of tip and stalk 
cells. Spheroids from M-ECs and F-ECs efficiently spread after 18h of incubation 
(Fig. 14A). But, when L-NAME (1 mM) was added, sprouting was inhibited only 
in F-EC spheroids (Fig. 14A). Quantification of the cumulative sprout length 
showed a reduction of about 50% in F-ECs whereas M-ECs were totally 
unaffected (Fig. 14B). Super imposable results were obtained when spheroids 
were formed by M-ECs and F-ECs silenced for eNOS expression (Fig. 14C). 
 
M-ECs are more dependent on proliferation also for in vitro angiogenesis 
We also performed the sprouting assay on spheroids from M-ECs and F-ECs 
mitotically arrested by the addition of mitomycin (500 ng/ml) to elucidate the 
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contribution of cell growth to in vitro angiogenesis. At variance with the scratch 
assay, sprouting was impaired in both M-ECs and F-ECS (Fig. 15A). However, 
the inhibitory effect on sprouting was significantly higher in spheroids from 
growth-arrested M-ECs (about 70%) in comparison to spheroids from 
mitomycin-treated F-ECs (about 30%) (Fig. 15B).  
 
All together, results shown in Figs. 14-15 further suggest that different 
mechanisms are responsible for migration and sprouting in F-ECs and M-ECs. In 
particular, F-ECs are crucially dependent on eNOS activity not only for their 
migratory phenotype but also for in vitro angiogenesis. At variance, M-ECs show 
a more important dependence on proliferation in both the phenomena.  
 
F-ECs form more frequently tip cells 
Results obtained by studying migration and in vitro angiogenesis strongly 
suggest that F-ECs might possess a more migratory phenotype when compared 
to M-ECs. We therefore tested the ability of F-ECs and M-ECs to form tip cells 
during the in vitro angiogenesis process. To test this hypothesis, we performed 
experiments with mosaic spheroids prepared by mixing in a 1:1 ratio GFP-
carrying M-ECs and Cherry Red-expressing F-ECs (Fig. 16A). Quantification of 
the number of sprouts emerging from mixed spheroids showed that the large 
majority of sprouts segregated only M-ECs or F-ECs. However, in sprouts where 
ECs of both sexes were present, Cherry-F-ECs were located as tip cells in about 
73% of the sprout (Fig. 16B). Notably, when mosaic spheroids were incubated 
in the presence of L-NAME (1 mM), the treatment significantly impaired the tip 
cell activity showed by F-ECs that was reduced to about 50% (Fig. 16B). Again, 
our results favor the hypothesis that F-ECs show a higher migratory phenotype 
strictly controlled by eNOS activity. 
  
Figures
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Figure 1. Metabolic activity in male and female HUVECs. The reducing 
ability of F-ECs (red bars) and M-ECs (green bars) was evaluated by MTT (A) 
and WST-8 (B) assays on cells incubated for 24 h in complete medium. Results 
are expressed as O.D., and no significant differences between F-ECs and M-ECs 
were detected (n=5 in MTT, and n=4-5 for F-ECs and M-ECs in WST-8 assays, 
respectively, t test). In (C), the total cellular ATP levels were measured on 
parallel wells. Results are expressed as A.U., and no significant differences were 
found (n=8-7 for F-ECs and M-ECs, respectively, t test). (D) The total ATP 
content was measured after 4 h of treatment with 2-DG (20 mM, horizontal 
bars) or rotenone (1 µM, diagonal bars). Result are expressed as percent of 
untreated cells (ctrl, set at 100%). **p<0.01 vs the corresponding control cells, 
One way ANOVA with Bonferroni’s test, n=3. 
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Figure 2. Hormone deprivation induces a decrease in metabolic activity 
and cell number in F-ECs and M-ECs. F-ECs and M-ECs were cultured in SM 
(SM, solid bars) or in ChM w/out phenol red (ChM w/out ph red, open bars), and 
48h later media were changed. MTT absorbance (A), total cellular ATP (B), and 
cell number evaluated by cell counting with the vital dye Trypan Blue (C) were 
measured after a further 48h of incubation. Results are expressed as percent of 
cells cultured in SM (SM, set at 100%) in (A) and (B), and as cell number x 10-
3/ml in (C). ***p<0.001, n=9-7 for F-ECs and M-ECs, respectively, in (A); 
*p<0.05, n=6-5 for F-ECs and M-ECs, respectively, in (B); *p<0.05, n=3 in 
(C). All statistical comparisons were performed versus the corresponding SM by 
using t test. 
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Figure 3. Sex hormones do not prevent the decrease in metabolic 
activity and cell number induced by hormone deprivation in F-ECs and 
M-ECs. Experiments were performed as described in Figure 2 on ECs cultured for 
48h in SM or ChM w/out ph red. During the last 48 h of incubation, media were 
changed, and cells in ChM w/out ph red were treated with vehicle (ethanol, open 
bars) or E2 (1 nM, vertical bars) before measurements of MTT (A), ATP (B), and 
cell number (C). Data are expressed as percent of cells cultured in SM (solid 
bar) in (A) and (B), or as cell number x 10-3/ml in (C). ***p<0.001, **p<0.01, 
*p<0.05 vs the corresponding SM; ns vs the corresponding ChM w/out ph red + 
vehicle; n=8-4-3 in (A), (B), and (C), respectively, t test. In (D), vehicle (open 
bar), E2 (1 nM, vertical bar), DHT (1 nM, horizontal bar), or E2 + DHT (squared 
bar) were added to ChM w/out ph red as described above. **p<0.001 vs SM, 
n=3, t test; ns vs ChM w/out ph red, n=3, One way ANOVA with Bonferroni’s 
test.  
 58 
 
 
 
 
Figure 4. CS-FBS is responsible for the decreased metabolic activity and 
cell number in F-ECs and M-ECs. (A) MTT absorbance was measured after 
48h of incubation in SM (solid bars) or SM w/out phenol red (vertical bars). MTT 
(B) and  cell number (C) were measured after 48h of incubation in SM (solid 
bars), ChM (cross-hitched bars) or ChM w/out ph red (open bars). *p<0.05, 
**p<0.01, ***p<0.001 vs the corresponding SM, n=13-12 for F-ECs and M-ECs, 
respectively, in (B), and n=4 in (C), One-way ANOVA with Bonferroni’s test. 
(D) MTT (left axis) and ATP (right axis) were measured after 48h of incubation 
in SM (solid bars), ChM + vehicle (cross-hitched bars), or ChM + E2 (1 nM, 
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diagonal bars). *p<0.05 vs SM, ns vs ChM + vehicle, n=3, t test. (E) ChM was 
replaced with ChM (ChM/ChM, open bars) or with SM (ChM/SM, diagonal bars), 
and MTT was measured after 48h of incubation. ***p<0.001 vs the 
corresponding SM, |||p<0.001 vs the corresponding ChM/ChM, n=3, t test. 
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Figure 5. Thyroid hormone does not prevent the decrease in metabolic 
activity and cell number in F-ECs and M-ECs. MTT (A) and  cell number (B) 
were measured after 48h of incubation in SM (solid bars), ChM (cross-hitched 
bars) or ChM + T3 (10 nM, squared bars). *p<0.05, **p<0.01, ***p<0.001 vs 
the corresponding SM; ns vs ChM, n=3, t test. In both graphs, F-ECs and M-ECs 
are red and green, respectively. 
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Figure 6. CS-FBS impairs in vitro angiogenesis. (A) MTT absorbance was 
measured after 48h of incubation in SM (solid bars), ChM (cross hitched bars) or 
ChM + VEGF + bFGF (each at 20 ng/ml, pointed bars). **p<0.01, ***p<0.001 
vs the corresponding SM; ns vs ChM, n=3, t test. (B) Representative images of 
spheroids from F-ECs embedded in collagen gels in the presence of SM (left 
panel) or ChM (right panel). Photographs were taken 24 h later. (C) 
Quantification of the cumulative sprout length emerging from spheroids from F-
ECs (red bars) and M-ECs (green bars).  ***p<0.001 vs the corresponding SM, 
§
p<0.05 vs female ChM,  n=7, t test. F-ECs and M-ECs are red and green, 
respectively. 
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Figure 7. Acetate and palmitic acid partially restore in vitro angiogenic 
phenotypes impaired by CS-FBS in F-ECs and M-ECs. Cell number was 
measured in F-ECs (A) and M-ECs (B) after 48h of incubation in SM (solid bars), 
ChM (open bars),  ChM + acetate (20 mM, horizontal bars), ChM + vehicle 
(ethanol/BSA, cross-hitched bars) or ChM + palmitic acid (250 µM, vertical 
bars). In (A), *p<0.05 vs SM, **p<0.01 vs ChM, ***p<0.001 vs ChM + vehicle, 
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n=3, t test; in (B), **p<0.01 vs SM, *p<0.05 vs ChM, 
&
p<0.05 vs ChM + 
vehicle, n=4, t test. E2 (1 nM) was added to ChM in the absence or in the 
presence of acetate (C) or palmitic acid (D), and the number of cell was 
measured after 48 of incubation. The presence of E2 did not affect the results. In 
(C), ***p<0.001 vs ChM, °°°p<0.001 vs ChM + E2; in (D), ***p<0.001 vs 
ChM + vehicle; °°°p<0.001 vs ChM + vehicle + E2, n=6, Two way ANOVA. In 
(E) and (F), the cumulative sprout length emerging from F-ECs (red bars) and 
M-ECs (green bars) was measured after 24h of incubation in SM (solid bars), 
ChM or ChM + vehicle (cross-hitched bars), ChM + acetate (20 mM, horizontal 
bars), or ChM + palmitic acid (250 µM, vertical bars). Data are expressed as 
percent of control, i.e. the cumulative sprouting from cells cultured in SM. In 
(E), ***p<0.001 vs SM, *p<0.05 vs ChM or ChM + vehicle; in (F), ***p<0.001 
vs SM, **p<0.01 vs ChM, °p<0.05 vs ChM + vehicle, n=4, t test. 
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Figure 8. The expression of eNOS is higher in F-ECs than in M-ECs. (A) 
Total eNOS protein was evaluated by western blotting on lysates prepared from 
M-ECs and F-ECs. β-actin was used as a loading control. Upper panel: a 
representative blot out of 14 is shown. Lower panel: densitometric analysis of 
eNOS protein expression in M-ECs (green bars) and F-ECs (red bars). 
**p<0.001; n=14. (B) eNOS RNA levels were measured by RT-qPCR and 
normalized to the level of the housekeeping gene 18S. ***p<0.001, n=3. In (C) 
and (D), eNOS protein was evaluated on lysates from twin M-ECs and F-ECs at 
P1 passage (C) or immediately collected after the flushing from cords (D). (E) 
eNOS dimers and monomers were separated by LT-PAGE as described in the 
“Materials and Methods” section. Upper panel: a representative blot out of 6 is 
shown. Lower panel: densitometric analysis of the dimer-to-monomer ratio in M-
ECs (green bars) and F-ECs (red bars). *p<0.05; n=6.  
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Figure 9. eNOS is not involved in the control of M-EC and F-EC 
proliferation. (A) M-ECs (green symbols) and F-ECs (red symbols) were 
cultured in SM, and WST-8 was added for the last 4 h of incubation at the 
indicated times.  (B) M-ECs (green bars) and F-ECs (red bars) were cultured in 
the absence (solid bars) or in the presence (horizontal bars) of L-NAME (100 
µM). Data are expressed as percent of control, i.e. cells cultured in SM (solid 
bars).  
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Figure 10. A different role for eNOS in the control of M-EC and F-EC 
migration. (A) Chemotaxis experiments were performed using 10% FBS as 
attractant. Results are expressed as the ratio between the number of migrating 
F-ECs and M-ECs, i.e. fold over M-ECs. *p<0.05, n=4-6 for M-ECs and F-ECs, 
respectively. (B) Chemotaxis toward FBS was performed with M-ECs and F-ECs 
in the absence (solid bars) or in the presence of L-NAME (100 µM, horizontal 
bars). Results are expressed as the number of migrating cells, and are the mean 
± s.e.m of 25 counts from a representative experiment, repeated 3 times with 
similar results. ***p<0.001 vs the corresponding untreated control cells (ctrl), 
&
p<0.05 vs M-ECs, t test. (C) Percent of L-NAME-induced inhibition of M-EC and 
F-EC migration. **p<0.001, n=3. In all graphs, M-ECs and F-ECs are green and 
red, respectively. 
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Figure 11. A different role for eNOS in the control of M-EC and F-EC 
migration. (A) Representative photographs of M-ECs and F-ECs were taken at 
the time of wounding (t 0h) and after a 15-Ԝh incubation in 20% FBS (ctrl) or in 
20% FBS supplemented with L-NAME (100 µM). (B) The graph represents the 
mean ± s.e.m. of the percent of wound closure at 15 h. CTRL cells, solid bars; L-
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NAME-treated cells, horizontal bars. *p<0.05, ***p<0.001 vs the corresponding 
CTRL cells, n=3-4 for M-ECs and F-ECs, respectively, t test. (C) Quantification of 
the percent of wound closure measured 15 h after the wound on M-ECs and F-
ECs transfected with scrambled (solid bars) or eNOS siRNA (squared bars). 
*p<0.05 vs the corresponding scrambled siRNA, n=3, t test. In (D), a 
representative blot out of 3 showing the degree of eNOS silencing in M-ECs and 
F-ECs.  
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Figure 12. M-ECs strictly depend on proliferation to close the wound. (A) 
Representative photographs of M-ECs and F-ECs were taken at the time of 
wounding (t 0h) and after a 15-Ԝh incubation in 20% FBS (ctrl) or 20% FBS 
containing mitomycin (500 ng/ml). (B) The graph represents the mean ± s.e.m. 
of the percent of wound closure at 15 h. CTRL cells, solid bars; mytomicin-
treated cells, vertical bars. ***p<0.001 vs the corresponding CTRL cells, n=3, t 
test. 
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Figure 13. Proliferation and migration are independent pathways in M-
ECs and F-ECs. Graphs represent the mean ± s.e.m. of the percent of wound 
closure measured after a 15-Ԝh incubation in 20% FBS (CTRL, solid bars), 20% 
FBS containing L-NAME (100 µM, horizontal bars) or mitomycin (500 ng/ml, 
vertical bars), and 20% FBS containing L-NAME + mitomycin (squared bars). 
*p<0.05, ***p<0.001 vs the corresponding CTRL cells, One way ANOVA with 
Bonferroni’s test, n=3. M-ECs (A) and F-ECs (B) are green and red, 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 71 
 
 
 
 
Figure 14. eNOS is essential for in vitro angiogenesis in F-ECs. (A) 
Representative images of spheroids from M-ECs and F-ECs embedded in collagen 
gels in the absence (CTRL) or in the presence of L-NAME (1 mM).  Photographs 
were taken 18h later. (B) Quantification of the cumulative sprout length from 
untreated M-EC and F-EC spheroids (CTRL, solid green and red bars, 
respectively) or from L-NAME-treated spheroids (horizontal bars, green and red 
for M-ECs and F-ECs, respectively). **p<0.01 vs the corresponding CTRL, n=3, t 
test. (C) Quantification of the cumulative sprout length from M-EC and F-EC 
spheroids obtained from cells transfected with scrambled (solid bars) or eNOS 
siRNA (squared bars). M-ECs and F-ECs are green and red, respectively. 
**p<0.01 vs scrambled, n=3, t test. 
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Figure 15. M-ECs are more dependent on proliferation also for in vitro 
angiogenesis. (A) Representative images of spheroids from M-ECs and F-ECs 
embedded in collagen gels in the absence (CTRL) or in the presence of 
mitomycin (500 ng/ml).  Photographs were taken 18h later. (B) Quantification 
of the cumulative sprout length from untreated M-EC and F-EC spheroids (CTRL, 
solid green and red bars, respectively) or from mitomycin-treated spheroids 
(vertical bars, green and red for M-ECs and F-ECs, respectively). *p<0.05, 
**p<0.01 vs the corresponding CTRL; 
§
p<0.05 vs mitomyicin-treated F-ECs, 
n=5-4 for M-ECs and F-ECs, respectively.  
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Figure 16. F-ECs form more frequently tip cells. (A) Representative 
fluorescence photographs of a mosaic spheroid containing a 1:1 mixture of GFP-
M-ECs and Cherry-F-ECs embedded in collagen gels. Photographs were taken 
18h later. The arrowhead indicates a F-EC located as tip cell in a sprout 
containing both GFP-M-ECs and Cherry-F-ECs. (B) Quantification of the percent 
of tip cell contribution in sprouts containing both GFP-M-ECs and Cherry-F-ECs 
emerging from control spheroids (CTRL) or from L-NAME-treated spheroids. 
*p<0.05, n=17.  
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Atherosclerosis and CVD are classical examples of diseases where sex/gender 
differences have been described. A significant body of evidence suggests that 
CVD is less prevalent in women than men until midlife, and the female 
advantage in younger women has been attributed to estrogens, which are lost 
with menopause10,25,26. Since the earliest event in the onset of atherosclerosis 
and CVD is endothelial dysfunction (ED), many studies have been focused on 
endothelium. But, despite well-established epidemiological and clinical 
evidence of a different prevalence of CVD in young men and women, studies 
involving endothelial cells (ECs) do not frequently identify the sex of cells 
(even when the effects of sex hormones are analyzed), and very little is 
known about innate sex properties of male and female ECs (M-ECs and F-ECs, 
respectively). Therefore, we started our study with the aim to investigate the 
in vitro properties of human primary M-ECs and F-ECs, focusing on their 
metabolism and the expression and activity of eNOS. 
 
Almost all of our knowledge about biochemical and signaling pathways, and 
more generally about biological processes, has been provided by established cell 
lines. However, sex has been rarely considered as a relevant biological 
variable23, and this asexual approach has limited the understanding of potential 
sex-based differences not only in basic biological functions but also in patho-
physiological mechanisms22,23,24. Moreover, increasing evidence suggest that 
cells differ according to sex, regardless of their exposure to sex hormones. For 
that reason, researchers are always more encouraged to pay close attention to 
sex as a relevant biological variable in their studies. With this aim, the National 
Institutes of Health (NIH) has announced that sex will be taken into account in 
the research designs, analyses, and reporting in vertebrate animal and human 
studies. Similarly, the European Research program Horizon2020 asks in most of 
its calls for the inclusion of sex/gender aspects. 
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 Along with these general comments, the knowledge of the sex of cells becomes 
decisive when they are used for in vitro studies on sex/gender-dependent 
pathologies. As a matter of fact, some differences are reported when primary 
cultures of human M-ECs and F-ECs have independently been studied. 
Prostacyclin and prostaglandin E2 synthesis is for example more efficiently 
stimulated by thrombin in M-HUVECs than in F-HUVECs28. Another study reports 
that M-HUVECs express higher levels of autophagic markers than F-HUVECs30. A 
whole genome expression analysis recently demonstrates a higher expression of 
immune-related genes and a stronger transcriptional response to shear stress in 
F-ECs compared to M-ECs31. Differences have also been reported in other cells of 
the vascular system, i.e. in VSMCs, where RLIP76 - a cell surface protein that 
catalyzes the extrusion of reduced glutathione (GSH) conjugates – alters more 
efficiently the intracellular redox balance, C-Jun kinase signaling activation, and 
apoptosis in F-VSMCs than in M-VSMCs29.  
 
With the aim of further discovering putative differences between M-ECs and F-
ECs, we started our experiments by comparing their metabolic properties. Some 
phenotypic metabotype differences between males and females have been 
described by a genome-wide analysis performed on serum of more than 2.000 
subjects86. No data are currently available on a possible dimorphism in EC 
metabolic genes and bio-markers. Until now, it is well-known that ECs are 
strictly dependent on aerobic glycolysis84,87,88, and only partially rely on 
oxidative metabolism, for ATP production. Indeed, it has been demonstrated that 
HUVECs maintain unchanged levels of ATP even at very low O2 concentrations, 
and that the EC production of ATP is significantly affected only by interfering with 
the glucose metabolism88. We have fully confirmed these data, finding that 
aerobic glycolysis contributes for about the 80%, and oxidative metabolism for 
about the 20%, to the maintenance of steady-state cellular ATP levels. However, 
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we do not find any difference in the bio-energetic requirement of F-ECs and M-
ECs, thus showing for the first time that ECs of both sexes mainly depend on 
glycolysis for ATP generation. It should be pointed out that the measurement of 
a steady-state parameter as the total cellular ATP content might conceal some 
sexual dimorphic differences possibly existing between M-ECs and F-ECs. More 
detailed metabolic analyses, such as the measurement of the energy charge, i.e. 
the ADP/ATP ratio, or the capacity of consuming glucose over time, will be 
performed to further deepen the knowledge about putative sex-specific 
differences in EC metabolism.   
 
The greater incidence of CVD in men and post-menopausal women - compared 
with pre-menopausal women - implies the existence of a vaso-protective 
phenotype in the young female population. Since sex hormones – especially, 
estrogens - are believed to be responsible for these defensive effects, we 
decided to study their regulatory role on metabolic properties in human M-ECs 
and F-ECs. Surprisingly, we consistently observed a significant decrease in cell 
number - and consequently in metabolic activity - when M-ECs and F-ECS have 
been cultured in a medium supplemented with charcoal-stripped serum (CS-FBS) 
commonly used for in vitro studies on hormone activities. Furthermore, the 
presence of CS-FBS totally abrogates the ability of F-EC and M-EC spheroids to 
sprout in an in vitro angiogenesis assay, thus affecting a functional property 
distinctive of ECs.  
 
Charcoal-stripped serum is largely used in cellular, biological, and 
pharmacological studies. The stripping procedure reduces or depletes the 
concentration of many biologically active substances such as steroids, thyroid 
and peptide hormones, vitamins, electrolytes, enzymes, metabolites, and 
lipids80,81,85. Some alterations in cell signaling and differentiation have been 
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described in cells cultured in CS-FBS in comparison to their counterpart grown in 
normal serum89,90. Furthermore, the growth of human CFU-megacaryokytes is 
improved when cells are cultured in CS-FBS91 whereas the mouse osteoblastic 
cell line MC3T3-E1 displays a limited growth and an impaired alkaline 
phosphatase expression in CS-FBS92. Again, CS-FBS modifies the phospholipid 
metabolism in type II rat pneumocytes85 and the cellular bioenergetics of breast 
cancer cells93. Regarding ECs, a variety of results describing the effects of sex 
hormones on their behavior have been obtained in cells cultured in media 
supplemented with CS-FBS. However, most of these studies did not refer to cell 
proliferation even if they involved cells grown in CS-FBS for at least 24-48 h94,95,  
and also when hormones different from estrogens were studied96,97. To our 
knowledge, up to now no data are available on the direct comparison of ECs 
grown in normal or CS-FBS. In our experiments, we consistently observed a 
reduced F-EC and M-EC growth when CS-FBS was used, advising about the 
disregarded contribute of CS-FBS to data obtained from ECs cultured in 
nominally hormone-free media. More importantly, F-ECs and M-ECs also lose 
some of their typical properties when cultured in CS-FBS, i.e. the ability to 
sprout, thus favoring the idea that FBS component(s) lost in CS-FBS possess 
broad implications in EC physiology.   
 
A crucial question arising from our results concerns the failure of sex hormones 
in preventing the inhibitory effects on cell growth and sprouting we described in 
ECs of both sexes cultured in CS-FBS. In a collaborative study, we recently found 
the expression of ERs, GPER, and androgen receptors (ARs) in both F-ECs and 
M-ECs30, thus suggesting that lack of effect may not be due to the absence of 
receptor expression. However, controversial data are reported in the literature 
on ER and AR expression in HUVECs, since some authors report the absence98,99 
– or, at least, a weak expression100,101 - of classical ERs. On the contrary, 
   79
Annibalini et al.102 show that F-ECs and M-ECs express both ERβ and ARs while 
ERα are absent. Other events - such as a loss in ER activity due to an increase in 
ER methylation during in vitro passages of ECs102 – may also be excluded as 
responsible for the inability of sex hormones to prevent reduced cell growth and 
sprouting, since our experiments have been performed on low passage ECs (1-
4).  
It should be pointed out that most of the in vitro studies on E2 and ECs focus on 
the hormone ability to improve EC functions through an increase in eNOS 
expression and activity. However, these findings have been frequently obtained 
in ECs from other species – among these, the bovine aortic ECs (BAECs) are 
often used for biochemical studies on eNOS expression103 – or in immortalized 
model of ECs – such as the somatic cell hybrid EA.hy926, deriving from HUVECs 
fused with the human lung carcinoma cell line A549104,105, or the EC.304 cells, 
now identified as a human bladder cancer cell line106. Similarly, the proliferative 
effect of E2 on ECs has been reported for example in BAECs107 or in media not 
containing CS-FBS108. We can therefore propose that HUVECs cultured in CS-FBS 
are not the best model to study hormonal effects in ECs. This observation is also 
sustained by the results obtained by re-adding thyroid hormone that, despite its 
well-known pro-angiogenic properties109, does not prevent the CS-FBS-induced 
inhibitory effects on ECs.  In conclusion, our data showing that CS-FBS impairs 
the in vitro HUVEC distinctive properties - irrespective of the sex of cells and of 
the presence of sex and/or thyroid hormones - may be part of a more general 
discussion on serum starvation and on its interfering potential with experimental 
results and conclusions110. But they also support the idea that CS-FBS loses one 
or more component(s) showing broad implications in EC physiology. This 
hypothesis is strongly supported by the observation that re-addition of normal 
serum totally restores the metabolic activity of F-ECs and M-ECs previously 
grown in CS-FBS. 
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In addition to various hormones and peptides, charcoal stripping also removes 
lipids from FBS85. This defeat is potentially rather important since metabolism is 
emerging as a crucial regulator of EC physiology, especially angiogenesis72. In 
particular, FAs have been reported to be crucially involved in the regulation of EC 
proliferation75. Their oxidation to acetyl-CoA generates a carbon source required 
in ECs for the synthesis of nucleotides necessary for DNA replication75. Indeed, 
the genetic or pharmacological block of FAO impairs EC proliferation, vessel 
sprouting, and angiogenesis both in vitro and in vivo75. Interestingly, this central 
role of FAO seems to be exclusive for ECs since most cells do not use FAs for 
DNA synthesis75. Our results, showing the ability of acetate and palmitic acid to 
partially prevent the decrease in cell number and sprouting induced by the CS-
FBS containing medium, clearly suggest that lipids are one of the crucial 
components of serum lost in CS-FBS and required for the maintenance of EC 
growth and in vitro morphogenetic properties. Our data also confirm the central 
role of FAs and FAO in the control of EC proliferation and sprouting. Again, as 
discussed above for the ATP-dependence on glycolysis, differences between F-
ECs and M-ECs are not  evident.  
 
Collectively, all the results discussed above demonstrate that F-ECs and M-ECs 
do not significantly differ in their metabolic properties showing a comparable 
dependence on glycolysis for ATP generation and on FAs/FAO for cell growth and 
sprouting. The use of CS-FBS should be discouraged in ECs since the lack of 
lipids profoundly alters EC physiological properties, thus suggesting caution in 
the interpretation of results obtained in ECs cultured in CS-FBS-containing 
media. 
 
Searching for differences between F-ECs and M-ECs, we focused on eNOS,  the 
enzyme responsible for NO formation. In our previous work30, we anticipated 
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that eNOS expression – both at mRNA and protein levels - is higher in F-ECs in 
comparison to M-ECs. Here, we confirm these results in another set of donors. 
But, very importantly, we demonstrate that: i) the difference in eNOS expression 
is conserved when M-ECs and F-ECs are derived from twin donors; ii) eNOS is 
more expressed in F-ECs even when cells are collected immediately after the 
flushing from cords, i.e. without any in vitro passage. This latter result is of 
particular relevance since it shows for the first time that the enhanced eNOS 
expression in F-ECs may be considered an inborn feature, and not an in vitro 
acquired attribute. 
 
To investigate the biological significance attributable to the higher eNOS 
expression in F-ECs, we analyzed its involvement in EC physiology starting from 
proliferation. Our results show that FBS-induced growth is independent on eNOS 
activity both in F-ECs and M-ECs. This result is not surprising since a number of 
data in the literature exclude a role for eNOS in FBS-induced proliferation111,112. 
However, we demonstrate that the independence of FBS-induced proliferation of 
eNOS is unrelated to sex in ECs.  
 
Beside proliferation, migration is another critical EC property strictly involved in 
the angiogenic process. At variance with proliferation, a number of papers 
demonstrate that eNOS-derived NO facilitates EC migration, both in chemotaxis 
and in the scratch assays111,113. In addition, it has been demonstrated that the 
activation of eNOS – by phosphorylation at Ser1177 - stimulates EC migration 
even in the absence of chemotactic gradient113. However, the contribution of 
eNOS to F-EC and M-EC motility has never been studied.  Our data demonstrate 
for the first time that F-ECs show a greater migratory capability in comparison to 
M-ECs in the chemotaxis assay, and that eNOS is crucially required for migration 
only in F-ECs.  Indeed, the pharmacological inhibition of eNOS more significantly 
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reduces the chemo-tactic response in F-ECs than in M-ECs. The divergence is 
even more dramatic in the scratch assay, where L-NAME - or eNOS silencing - 
totally block the ability to close the wound in F-ECs, leaving almost unaffected 
the capability of M-ECs of closing the gap.  Therefore, we can conclude that only 
F-ECs are critically dependent on eNOS to migrate. This conclusion is also 
supported by immune-fluorescence experiments (still ongoing in our laboratory, 
and too preliminary to be included in this thesis) that suggest the presence of a 
higher amount of lamellipodia – the protrusions characterizing the leading edge 
of migrating cells114 -  on F-EC membranes. Moreover, we have also observed a 
prevalent eNOS localization at lamellipodia only in F-ECs. 
 
Taking into account the different involvement of eNOS in the regulation of EC 
proliferation and migration – where proliferation is eNOS-independent - it is 
remarkable that M-ECs, at variance from F-ECs, are sensitive to the proliferative 
block induced by mytomycin treatment. Indeed, only M-ECs are significantly 
impaired in the wound closure when mitotically arrested. These results 
emphasize the almost complete independence of M-ECs on the contribution of 
eNOS activity and their dependence on proliferation rather than migration in the 
wound  closure.  
 
Collectively, these results suggest that proliferation and migration are regulated 
through two independent pathways - eNOS-independent and eNOS-dependent, 
respectively - in M-ECs and F-ECs. Moreover, these two processes show a 
different relevance in M-EC and F-EC behavior. M-ECs mostly depend on eNOS-
independent proliferation to close the wound. At variance, F-ECs possess a more 
motile phenotype and require eNOS for their activities.  Therefore, we can 
conclude that different mechanisms underlie migration in F-ECs and M-ECs.  
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The disparity between M-ECs and F-ECs in terms of dependence on eNOS activity 
is even more evident when cells are compared in an in vitro model of 
angiogenesis. It is well-established that the formation of blood vessels requires 
migration and proliferation of ECs. Sprouting angiogenesis is indeed the result of 
a coordinated process where the growth of new blood vessels relies not only on 
the migration of specialized cells at the forefront of vascular sprouts – the tip 
cells – but also on trailing cells that undergo proliferation to elongate the branch 
– the stalk cell68,70,115. Here, we show that eNOS activity is fundamental in F-ECs 
also for branching formation. On the contrary, M-ECs fully retain their ability to 
sprout even in the presence of L-NAME or when eNOS is silenced, thus 
confirming their eNOS-independence. Conversely, M-EC spheroids are much 
more impaired when proliferation is blocked in comparison to F-EC spheroids.  
These data may partially explain the lower sprouting observed in M-ECs in 
comparison to F-ECs cultured in CS-FBS. In this experimental condition, the 
absence of FAs - and the consequent impairment in FAO - compromises the 
proliferative process, leading to a more remarkable impairment in M-EC 
sprouting. From the analysis on mosaic spheroids from GFP-carrying M-ECs and 
Cherry Red-expressing F-ECs, it emerges that F-ECs are preferentially located at 
the forefront of the sprouts, thus showing for most of the time the tip migratory 
phenotype. At variance, M-ECs mostly constitute the core of the sprout. Notably, 
the frequency of F-ECs in the tip position significantly decreases in the presence 
of L-NAME, thus confirming again that the migratory phenotype that characterize 
F-ECs is crucially controlled by eNOS activity.  
 
It is therefore possible to suggest that in vitro angiogenesis depends on different 
mechanisms in F-ECs and M-ECs. More precisely, F-ECs mainly contribute to the 
branching development via eNOS-dependent migration, whereas M-ECs 
participate to the process through eNOS-independent proliferation. In F-ECs, the 
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higher expression and activity of eNOS lead to the prevalence of a migratory 
phenotype. At variance, M-ECs rely on a different pathway that favors a 
proliferative phenotype possibly through the enhancement of FAO, thus 
permitting the overcoming of their lower migratory ability. In other words, F-ECs 
and M-ECs are able to achieve the same results, i.e. angiogenesis, but via 
different strategies, represented by motility for F-ECs, and proliferation for M-
ECs.   
 
In conclusions, our results demonstrate that different mechanisms – eNOS-
dependent and –independent, respectively - are responsible for migration and 
sprouting in F-ECs and M-ECs. The constitutive higher expression of eNOS in F-
ECs, and the crucial requirement of its activity for motility and sprouting, might 
contribute to the protection against CVD characteristic of the younger female 
population. Due to the critical dependence of F-ECs on its activity, any minimal 
loss in eNOS availability might therefore have harmful consequences on the 
female endothelial function.  
 
In addition, our results - even if restricted up to now to an in vitro approach -  
make some contribution to the sex-related research in the cardiovascular field, 
with the aim to take part in the development of precision medicine. Therapeutic 
interventions  have been traditionally designed to equally treat large populations 
of individuals – the “one-size-fits-all” approach. Conversely, precision medicine – 
defined as “an emerging approach for disease treatment and prevention that 
takes into account individual variability in genes, environment, and lifestyle for 
each person” by the NIH - is now becoming a benchmark in pharmacology. From 
this perspective, it is important to increase knowledge on the divergence in the 
onset and development of CVD between men and women, and on the gender 
dimorphic profiles that are emerging in terms of drug efficacy. As a 
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consequence, the elucidation of the biological basis for sex differences in CVD 
can lead the way to the development of gender-oriented preventive and 
pharmacological treatments.  
 
Future progress of the project 
To date, our findings are limited to an in vitro approach, even if our results have 
been obtained in a well-established and consolidated human primary EC model. 
Therefore, further investigations with the support of different models and/or 
methodological approaches are required to confirm and increase the knowledge 
and scientific significance of sex-based differences in male and female EC 
behavior. 
 
With the aim of studying if the higher expression of eNOS - already present at 
born in F-ECs – is maintained during lifetime, we will  extend our analyses to an 
ex vivo model represented by expanded endothelial progenitor cells (EPCs). EPCs 
express a variety of cell surface markers similar to those expressed by ECs and 
are involved in the maintenance of endothelial integrity and in the promotion of 
vascular repair116. Importantly, the number of circulating EPCs is reduced in 
CVD, and low EPC levels confer an increased risk of atherosclerotic disease 
progression and adverse cardiovascular outcome. Therefore, the study on EPCs 
from peripheral blood represents an innovative strategy to evaluate endothelial 
compartment through a non-invasive method.  
EPCs will be isolated from peripheral blood samples and cultured to form colonies 
(endothelial colony-forming cells, ECFCs)117 that will be used to analyze eNOS 
expression and function. To this purpose, we have already started the collection 
of ECFCs from healthy young women (age 20–40 yrs), perimenopausal women 
(40-55 yrs), and women in physiological menopause (55-70 yrs) assuming (or 
not assuming) hormone replacement therapy. EPCs from matched-age healthy 
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men will be concomitantly collected, expanded, and analyzed. EPCs collection, 
isolation, and expansion will be performed in collaboration with Prof.ssa Silvia 
Della Bella (Dept of Medical Biotechnology and Translational Medicine, 
BIOMETRA, University of Milano).  
 
 
  
Materials and Methods
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Cell cultures  
Human umbilical vein endothelial cells (HUVECs) were isolated from freshly 
derived umbilical cords essentially as described by Jaffe et al.118. Cords were 
anonymously donated after informed consent according to the national ethical 
legislation, and gently collected by gynecologists and nurses of the Macedonio 
Melloni Hospital. Umbilical cord vein was cannulated with a butterfly needle (0,8 
mm) and then washed with abundant sterile saline solution (0.9% NaCl) to 
remove blood clots. Afterwards, the vein was sealed at one end with a clamp and 
filled with a collagenase solution (0.125%) solubilised in Ca2+/Mg2+ phosphate-
buffered saline (PBS) buffer prepared by mixing 4 volumes of part A - containing 
NaCl 140 mM, KCl 3.9 mM, KH2PO4 2.1 mM, Na2HPO4 8.1 mM - with 2 volumes of 
part B - containing CaCl2 1.3 mM and MgCl2 0.93 mM. After 10 minutes of 
incubation at 37°C, the collagenase solution was collected in a 50-ml tube with 
an equal volume of 199 medium supplemented with 10% of fetal bovine serum 
(FBS).  Cells were finally harvested by centrifugation and plated on 25 cm2 flasks 
previously coated with 0.1% gelatin. HUVECs were routinely grown in 199 
medium supplemented with 20% FBS, 25 µg/ml endothelial cell growth 
supplement (ECGS) and 50 µg/ml heparin, and used at passages 1-4. Notably, 
we always used HUVECs pooled from two or more donors to minimize the 
variability associated with cells derived from a single male or female newborn 
donor.  
Charcoal stripping of FBS was performed following standard protocols80. Briefly, 
dextran-coated charcoal - obtained by overnight incubation of 2.5% w/v charcoal 
with 0.025% w/v dextran T-70 in PBS - was re-suspended in FBS and stirred 
overnight at 4°C. After centrifugation, the stripped FBS was sterilized by 
filtration through a 0.22 µm filter. Notably, charcoal stripping was applied to the 
same lot of serum present in the standard medium.  
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Cell metabolism assays  
Viable cell metabolism was measured by using the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) tetrazolium reduction assay. In 
metabolically active cells, the MTT substrate - prepared as a stock solution of 5 
mg/ml in PBS and added at a final concentration of 0.5 mg/ml - is converted into 
a purple insoluble formazan product that is solubilised in DMSO after 4 h of 
incubation at 37°C. In addition, we also performed experiments with WST-8 
(Dojindo), a highly water-soluble tetrazolium salt giving a yellow-color formazan 
dye when reduced by cellular dehydrogenase activities. The total cellular ATP 
content was evaluated by means of the CellTiter-Glo® Luminescent Assay 
(Promega, following the manufacturer’s instructions. All assays were performed 
on HUVECs plated at a density of 1.5x104 cells/well in 0.1% gelatin-coated 96-
well microplates. For the ATP assay, white plates were used to maximize light 
output signal. Optical density at 570 nm for MTT and  450 nM for WST-8, and 
luminescence for ATP were measured using a multiplate spectrophotometer 
(Victor™, PerkinElmer). All assays were performed in triplicate. 
Evaluation of cell number and viability 
Cell number and viability were assessed by the trypan blue exclusion test on 
HUVECs plated in 0.1% gelatin-coated 35-mm Petri dishes. 
Cell proliferation assay 
HUVECs were seeded in triplicate at a density of 2.000 cells/well in 0.1% gelatin-
coated 96-well plates, and cell proliferation was measured by WST-8 assay, 
according to the manufacturer’s instructions. The absorbance was measured at 
450 nm after 4h of incubation at 37°C. 
Cell migration assays 
Cell migration was detected by chemotaxis experiments in a 48-well modified 
Boyden’s chamber as described119. Briefly, after suspension in 199 medium 
containing 1% fatty acid free bovine serum albumin (FFA-BSA), HUVECs were 
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added to the upper chamber at a density of 5.0x104 cells/well. 
Polyvinylpyrrolidine (PVP)-free polycarbonate filters (8 µm pore size, 
Neuroprobe) - coated with type I collagen (10 µg/ml) -  were placed over a 
bottom chamber containing 10% FBS as attractant. After a 6-h incubation at 
37°C, the cells that had migrated to the lower side of the filter were stained with 
Diff-Quick stain (Neuroprobe), and 5 unit fields per filter were counted by a 
scorer blind to the experimental conditions using a Zeiss microscope.  
For the wound healing assay, a scratch wound was applied on confluent HUVECs 
using a sterile 200 µl pipette tip. Experiments were performed on cells plated in 
0.1% gelatin-coated 24-well plates. After the scratch, HUVECs were incubated in 
199 medium with 20% FBS in the presence of mitomycin (500 ng/ml) or L-NAME 
(100 µM), when indicated. Images were captured immediately after wounding 
(t0h) and 15 h later (t15h) at a 4x magnification with an Olympus U-CMAD3 phase 
contrast microscope equipped with an Olympus digital camera. The percent of 
wound closure (gap area at t0 minus gap area at t15h/gap area at t0 x100) was 
measured with the National Institute of Health (NIH) Image J software package.  
Three-dimensional (3-D) spheroid sprouting assay  
EC spheroids of a defined cell number were embedded into collagen gels in the 
presence of 25 ng/ml VEGF as previously described83,84. Briefly, a specific 
number of HUVECs (750 cells/well) was suspended in 199 medium containing 
10% FBS and 0.25% w/v methylcellulose, and seeded in non-adherent round 
bottom 96-well plates. Under these conditions, a single EC spheroid was 
assembled within 24 hours in every well. Spheroids (48-50 for each 
experimental samples) were quickly harvested and collected by a 5-min 
centrifugation at 500g. Each pellet was suspended in 199 medium with 20% FBS 
and 0.5% w/v methylcellulose, and the various test substances – VEGF, acetate, 
palmitic acid or its vehicle, and L-NAME at final concentrations of 25 ng/ml, 20 
mM, 250 µM and 1 mM, respectively – were added in a minimal volume to this 
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medium. Finally, an equal volume of a collagen stock solution - prepared by 
mixing at 4°C acidic rat tail collagen I (2 mg/ml; 8 vol) with 10x 199 medium (1 
vol) and 0.1 mM NaOH (approx. 1 vol) to adjust the pH to 7.4 – was added. The 
spheroid-containing gel was rapidly transferred into pre-warmed 96-well plates, 
and incubated at 37°C in 5% CO2. After 18 h, images were acquired with a 
phase-contrast microscope (10x objective magnification, Olympus U-CMAD3) 
equipped with an Olympus digital camera. In-gel angiogenesis was quantified by 
measuring the length of all of the capillary-like sprouts originating from 
individual spheroids using the NIH Image J program. At least, 10 randomly 
selected spheroids per experimental group were measured in each experiment. 
For mitotically inactivated HUVECs, mitomycin (500 ng/ml) was added overnight 
during the formation of spheroids. When silenced cells were used, HUVECs were 
plated to form spheroids 24 h after siRNA transfection.  
To assess male and female endothelial tip cell competition, M-ECs and F-ECs 
transduced with lentiviral vectors expressing GFP or CherryRed, respectively, 
were used.  Mosaic spheroids were prepared by mixing in a 1:1 ratio GFP-
carrying M-ECs and Cherry Red-expressing F-ECs. Lentiviral vector preparations 
- at a titer of 1-4x109 transducing units/ml - were a kind gift of Dr. Francesco 
Bifari, Dept of Medical Biotechnology and Translational Medicine, University of 
Milano. Images were obtained using a Zeiss LSM 510 Meta NLO confocal 
microscope.  
Immunoblot analyses 
For standard immunoblot analysis, HUVECs were washed with PBS and directly 
lysed in SDS-PAGE sample buffer (62 mM Tris-HCl pH 6.8, 2% sodium dodecyl 
sulfate (SDS), 10% glycerol, 5% 2-mercaptoethanol, and 0.04% bromophenol 
blue). After SDS-PAGE electrophoresis, proteins were transferred onto 
nitrocellulose membranes that were blocked with 5% (w/v) non fat dried milk in 
Tris-buffered saline (TBS: Tris-HCl 10 mM pH 8, NaCl 150 mM) containing 0.05% 
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Tween-20 (TBS-T). Filters were incubated overnight with the indicated primary 
antibodies (anti eNOS, 1:2.000, and anti β-actin, 1:1.000), and for 1 h with the 
appropriate peroxidase-conjugated secondary antibody (DAKO). The 
immunoreactive bands were visualized by chemiluminescence (LiteAblot Plus, 
EuroClone). For the detection of eNOS monomers and dimers, low temperature 
SDS-PAGE (LT-PAGE) was performed120. Briefly, HUVECs were lysed for 20 min 
on ice in a buffer containing Tris-HCl 20 mM pH 7.4, NaCl 150 mM, EDTA 5 mM, 
Na3VO4 1 mM, 1% NP-40 supplemented with a protease inhibitor cocktail (Sigma 
Aldrich). After centrifugation (10.000g, 15 min, 4°C), lysates were mixed with 
SDS-PAGE sample buffer and resolved by LT-PAGE with 6% gels without prior 
heat denaturation. All gels and buffers were kept at 4 °C during the whole 
procedure. Subsequent to LT-PAGE, the gels were transferred, and the blots 
were probed as routine Western blot. Densitometric analyses of the immunoblots 
were performed using the NIH Image J program. 
Total RNA extraction for reverse transcription and quantitative real time 
PCR (RT-qPCR) 
Total RNA was extracted using the RNeasy® Mini Kit and accompanying 
QIAshredder™ (Qiagen) according to the manufacturer’s instructions. A 15-min 
on-column incubation with DNase I (Qiagen) was performed, thus avoiding DNA 
contamination of samples. Reverse transcription was carried out using the 
SuperScript™ III First-Strand Synthesis System for RT-PCR (Thermo Fisher 
Scientific), again following the manufacturer’s instructions. For quantitative 
analysis of gene expression, we used the ABI Prism 7000 Sequence Detection 
System, SDS software version 1.2.3 (Applied Biosystems, CA, USA) with the 
TaqMan® Primer and Probe assays for human eNOS (NOS3, Hs00167166_m1) 
and for the endogenous control 18S (Hs99999901_s1). Sequences were 
amplified from 50 ng of cDNA. For calculation of results, the 2−∆∆Ct method was 
used allowing normalization to 18S. 
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Small interfering RNA (siRNA) transfection  
Validated StealthTM RNAi duplexes against human eNOS (GC content 48%) were 
provided from Thermo Fisher Scientific. As control RNA, we utilized a StealthTM 
RNAi negative control duplex (Medium GC Duplex, Thermo Fisher Scientific) with 
a 48% GC content, suitable for use as a control with StealthTM RNAi duplexes 
containing 45-55% of GC. All sets of RNAi molecules were individually 
transfected into HUVECs at a 10 nM concentration using the PepMute transfection 
reagent according to the manufacturer’s instructions (SignaGen Laboratories).  
The ability of the RNAi molecules to knockdown eNOS expression was analyzed 
by western blot analysis. 
Statistical procedures 
All data were expressed as mean ± s.e.m of at least 3 independent experiments. 
Statistical significance was determined by unpaired Student's t-test or by one-
way or two-way analysis of variance (ANOVA) followed by Bonferroni’s multiple 
comparison test, according to the number of groups compared. The GraphPad 
Prism version 5.00 software was used.  
Reagents and antibodies 
All tissue culture reagents were from Euroclone, except ECGS and heparin 
(Sigma Aldrich). Charcoal, dextran T-70, MTT, trypan blue, methylcellulose 
(product number M0512), L-NAME, sodium acetate, palmitic acid, and FFA-BSA 
were from Sigma Aldrich; rat tail collagen I from Serva; recombinant human 
VEGF165 and mitomycin from Peprotech; E2, DHT, and T3 from Cayman 
Chemical. Antibodies used were mouse monoclonals anti eNOS (BD Biosciences) 
and anti β-actin (Sigma Aldrich).  Palmitic acid was used as conjugate to FFA-
BSA. Briefly, a 75 mM stock solution of palmitic acid dissolved in ethanol were 
diluted 1:10 with a 10% FFA-BSA solution prepared in 199 medium, and 
incubated overnight at 37°C before every experiment.  
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